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Rehabilitation: the ﬁ fth pillar of 
the National Drugs Strategy
The mid-term review of the National Drugs Strategy (2005)1 recommended that rehabilitation 
become the fi fth pillar of the Strategy and that a working group be established to develop an 
integrated rehabilitation provision. The report of the Working Group on Drugs Rehabilitation was 
launched on 7 June 2007.2 The report makes a number of key recommendations and sets out the 
structural arrangements required to implement them. The overall goal is to provide an integrated 
rehabilitation service to current, stabilised and former drug users. This article summarises the main 
structural arrangements and recommendations in the report.
Structures for the delivery of rehabilitation services
National Drug Rehabilitation Implementation Committee and rehabilitation co-ordinators
A key proposal is to add to the existing structures of the drug strategy by establishing a National 
Drug Rehabilitation Implementation Committee (NDRIC), chaired by a senior rehabilitation co-
ordinator (new post). The committee will be made up of representatives of the Health Service 
Executive (HSE), the National Drugs Strategy Team (NDST), the National Advisory Committee on 
Drugs (NACD), the community and voluntary sectors, rehabilitation and healthcare professionals, 
problem drug users and families of problem drug users. In addition, it is proposed that 10 
rehabilitation co-ordinators and appropriate numbers of support staff be appointed. These co-
ordinators will contribute to the development of local protocols, service-level agreements, (SLAs) 
quality standards and care plans, and to the overall tracking of client progression. The report 
recommends that the co-ordinators join the treatment and rehabilitation sub-committees of local 
drugs task forces and take the lead in overseeing the implementation of the recommendations of 
the Working Group in their respective geographical areas. 
Recommendations 
Protocols, service-level agreements and quality standards
The Working Group recommends that the NDRIC develop broad national protocols to facilitate 
inter-agency working, which, when approved by the Cabinet Committee on Social Inclusion and 
the Inter-Departmental Group on Drugs, will form the basis for the development of local protocols 
(that will require fi nal approval by the NDRIC). The Group envisages that the protocols will cover 
issues such as confi dentiality, common assessment tools, referral procedures and confl ict resolution 
between agencies. It also recommends the development of SLAs at national and local level, to give 
clarity on the roles of each agency. The development of national and local SLAs will follow the same 
procedures as indicated for the development of inter-agency protocols. 
A quality standards framework should be developed for service providers, to include enhanced case 
management procedures. The framework will be set out by the NDRIC and will follow procedures 
similar to those proposed for the development of the protocols and SLAs. The framework will 
help to identify the core competencies required by service providers to enable them to deliver 
rehabilitation programmes. 
Case management, care plans and key workers
The HSE will be responsible for case management, for ensuring that this service is carried out by 
the responsible agency, and for tracking the progression of service users through the system. Case 
managers will liaise with key workers who will deal directly with clients receiving specifi c services. 
Client-centred care plans based on assessment, with negotiated and agreed goals, will form the 
basis of case management and progression. Care plans will be holistic and will address a range of 
personal, educational, housing and employment needs. 
Medical support
The report recommends an expansion in the range of treatment options, an increase in the number 
of local GPs and pharmacies, and an increase in the number of residential detoxifi cation beds from 
23 to 48 (HSE lead), pending the outcome of the report on residential treatment/rehabilitation.3 
Building on the work of the Research Outcome Study in Ireland (ROSIE),4 research should be 
undertaken to examine the outcomes of methadone maintenance programmes.
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Community Employment (CE) (vocational 
rehabilitation)
The health requirements (HSE lead) and 
educational requirements (Vocational Education 
Committee (VEC) lead) of CE participants should 
be addressed while they are on the scheme, 
with the help of service-level agreements. 
The number of drug-specifi c CE places should 
be increased from 1,000 to 1,300 to refl ect 
demand and the settling down of the regional 
drugs task forces (FÁS lead). A pre-stabilisation 
initiative, focusing on preparation for CE, should 
be developed (HSE lead). 
Employment
Stronger links with employers, employer 
organisations and trade unions need to be 
established to facilitate ease of access to the 
workplace for recovering drug users (Department 
of Enterprise, Trade and Employment lead), 
while access to ongoing support for employers 
of drug users and for recovering drug users in 
employment is recommended (Case managers 
and rehabilitation co-ordinators lead). The report 
recommends that research on progression 
pathways to employment should be undertaken 
(NACD lead).
Access to education
Factors that make it diffi cult for recovering 
drug users to access education should be 
identifi ed and removed where possible and an 
education fund for drugs rehabilitation should 
be established (Department of Education and 
Science lead). An outreach approach should 
be developed by the Vocational Education 
Committees to identify and develop responses 
to the adult educational needs of problem drug 
users in rehabilitation. 
Housing
Local authorities should liaise with local drugs 
task forces to facilitate recovering drug users 
who wish to return to or move into local 
authority housing in the community. Dedicated 
supported accommodation, staffed appropriately, 
should be provided to cater for clients who 
have diffi culties with an independent living 
environment. The provision of transitional/half 
way housing for recovering drug users should 
continue to be expanded. The long-term housing 
needs of problem drug users who are capable 
of independent living should be addressed, for 
example, through the rental accommodation 
scheme. (Department of Environment, Heritage 
and Local Government lead).
Rehabilitation of offenders
Drug treatment and rehabilitation programmes 
should be made available to all problem drug 
users in prison in the context of mandatory drug 
testing and drug-free prisons, and a continuum 
of care put in place for when they leave prison. A 
review of the operation of the local prison liaison 
groups should take place (Irish Prison Service and 
the Probation and Welfare Service lead). 
Childcare
The HSE, in conjunction with the Offi ce of the 
Minister for Children should decide on how best 
to integrate childcare facilities with treatment 
and rehabilitation services and subsequently 
progress the matter. Research is recommended 
to inform this process (HSE lead). Childcare 
services for children of problem drug users 
should adopt an approach focused on the 
development of the children (Offi ce of the 
Minister for Children lead). 
Role of families in the rehabilitation process
Service providers should actively encourage 
family reconciliation, where appropriate. 
Families should be seen as service users and 
involved in the recovery of drug using family 
members (Case managers, HSE and service 
providers lead). A pilot short-stay respite 
programme for families of drug users should be 
developed (HSE lead).
Conclusion
This report sets out a sound structural framework 
with key relevant recommendations to advance 
the strategic response to the rehabilitation needs 
of current, stabilised and former drug users. The 
report provides a real challenge to Government 
departments and agencies already involved – 
and those newly involved – in the delivery of 
the National Drugs Strategy to combine their 
expertise and energy towards delivering much 
needed rehabilitation services. In this regard, 
the development of inter-agency protocols and 
service-level agreements are vital to enable these 
different agencies to develop agreed strategic 
and operational goals. The development of a 
quality standards framework identifying the core 
competencies and associated training needs 
of service providers will add to the quality of 
services being provided. 
The recommendations in this report for the 
delivery of an expanded service, in terms of 
treatment options, educational and vocational 
training options, and employment supports, 
are a welcome addition to the National Drugs 
Strategy. These services should build on the 
achievements of the strategy thus far and 
contribute to the social reintegration of current, 
stabilised and former drug users. Finally, the 
appointment of rehabilitation co-ordinators and 
the establishment of the NDRIC will be followed 
by the development of an agreed action plan, 
with key performance indicators to assess outputs 
and measure outcomes. 
(Martin Keane)
Steering Group for the mid-term review of 1. 
the National Drugs Strategy (2005) Mid-term 
review of the national drugs strategy 2001-
2008. Dublin: Department of Community, 
Rural and Gaeltacht Affairs.
Working Group on Drugs Rehabilitation 2. 
(2007) National drugs strategy 2001–2008: 
rehabilitation. Report of the working group 
on drugs rehabilitation, May 2007. Dublin: 
Department of Community, Rural and 
Gaeltacht Affairs. 
This report is being fi nalised by the HSE 3. 
Working Group on Residential Treatment & 
Rehabilitation (Substance Users) and will be 
published in due course.
See article on ROSIE Findings 4 on p. 9 of 4. 
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Rehabilitation report (continued)
3In April 2007 the fi nal departmental reports on the 
completion of An agreed programme for government, 
which set out the priorities of the Fianna Fáil–Progressive 
Democrats coalition government 2002–2007, were 
released.1 They include updates on the fi ve drug-related 
initiatives not included in the National Drugs Strategy 
2001–2008. 
We will provide for compulsory drugs testing of prisoners 
where appropriate. 
The Department of Justice, Equality and Law Reform 
stated: ‘Section 35 of the Prisons Act 2007 provides that 
the Minister may make rules for the regulation and good 
government of prisons. In line with this provision, the Prison 
Rules 2007 are currently in the fi nal stages of being drafted. 
It is envisaged that the new rules will come into effect 
approximately three months after the enactment of the Bill. 
… Amongst other things, the new Rules will provide for the 
compulsory testing and searching of prisoners for drugs and 
other contraband. Under the Rules it shall be a breach of 
prison discipline for a prisoner to be found in possession of 
any controlled drug or medicinal product other than that 
which has been prescribed by the prison medical authorities. 
A prisoner shall also, if requested by a person acting on 
the authority of the prison governor, provide samples of 
urine, saliva, oral buccal transudate or hair for the purpose 
of detecting the presence of intoxicating liquor, controlled 
substances or medicinal products.’ 
Where a person has been found to be involved in the 
supply of drugs to a prisoner we will introduce a stiffer 
penalty. 
We will require convicted drug dealers to register with 
the Gardaí after leaving prison.
The Department of Justice, Equality and Law Reform 
reported that relevant provisions in respect of both these 
initiatives had been included in the Criminal Justice Act 
2006, and Commencement Orders made.
We will ensure that an early warning system, involving all 
key agencies, is in place to track the potential spread of 
heroin into new areas. 
The Department of Community, Rural and Gaeltacht Affairs 
reported, ‘… the National Advisory Committee on Drugs 
(NACD) has sought expressions of interest from appropriate 
bodies to develop a Drug Trend Monitoring System (DTMS) 
as part of its current work programme and these are due in 
April 2007. If progressed, such a system will collect primary 
data, as well as analysing secondary data on a range of drug 
use indicators in order to identify nationwide trends in drug 
use, including the spread of heroin use outside of Dublin.’
We will continue to prioritise heroin and cocaine for 
intervention, and will publish separate national targets 
for supply reduction for each major type of drug.
The Department of Community, Rural and Gaeltacht 
Affairs reported, ‘The increased use and spread of cocaine 
has emerged as a particular threat, and in late 2006, the 
National Advisory Committee on Drugs (NACD) and the 
National Drugs Strategy Team (NDST) compiled a briefi ng 
paper on cocaine and a presentation covering this and other 
drug related issues was made to the Cabinet Committee on 
Social Inclusion. Implementation of the recommendations 
in the cocaine paper are being progressed with the relevant 
Departments and agencies.’ (In its 2005 Progress Report, 
the government reported that it had accepted the existing 
key performance indicators in the National Drugs Strategy, 
and would not specify separate targets for each major type 
of drug.) 
The drugs issue and social inclusion
In its Agreed Programme, under the heading ‘Building 
an inclusive society’, the government included an action 
to promote and pilot local corporate social responsibility 
initiatives, for example, in areas affected by drugs and 
social or rural disadvantage. In its fi nal progress report in 
respect of this action, the Department of Community, Rural 
and Gaeltacht Affairs stated, ‘Government has established 
a Forum on Philanthropy to examine ways of facilitating 
greater levels of philanthropic activity within Ireland. The 
Department has provided funding of €100,000 per annum 
to Philanthropy Ireland in support of this initiative.’ 
Under the heading ‘Regenerating urban communities’, 
the government pledged to continue the Young People’s 
Facilities and Services Fund (YPFSF) and complete a 
comprehensive survey of the availability of recreation facilities 
in disadvantaged areas. In its fi nal report, the Department of 
Community, Rural and Gaeltacht Affairs stated: ‘To date, the 
focus of the YPFSF has been in the 14 LDTF areas, as well in 
the four urban centres of Limerick, Waterford, Galway and 
Carlow. Overall to date, approximately €109m has been 
allocated to support projects employing around 330 people. 
… 108 services projects, with an annual cost of approximately 
€7.6m, were evaluated and mainstreamed to the Department 
of Education and Science between 2004 and 2006. They 
continue to receive annual funding directly from that 
Department. Expenditure under the YPFSF in 2006 amounted 
to just over €15.5m (€5.8m capital; €9.7m current).’ 
(Brigid Pike)
1. Fianna Fáil and the Progressive Democrats (2002) An 
agreed programme for government between Fianna Fáil and 
the Progressive Democrats. Dublin: Fianna Fáil and the 
Progressive Democrats. See Drugnet Ireland, Issues 8, 12 
and 16 for updates on the annual Progress Reports for 
2003, 2004 and 2005. No progress report was released in 
2006. The fi nal departmental progress reports are available 
on the website of the Department of the Taoiseach www.
taoiseach.gov.ie. Retrieved on 15 June 2007.
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4The regional drugs task forces (RDTFs) are tasked with co-
ordinating the implementation of drug policy, as set out in 
the National Drugs Strategy, in the regions. In 2006 the fi rst 
round of RDTF strategies and/or action plans was released. 
Previous issues of Drugnet Ireland have looked at the overall 
approach taken by the RDTFs and at their responses to the 
need for co-ordination.1 Starting with supply reduction, 
this and the following three issues of Drugnet Ireland will 
consider the RDTFs’ responses to each of the four pillars of 
the National Drugs Strategy.
The RDTFs acknowledge that national statutory bodies – An 
Garda Síochána, the Probation and Welfare Service, the 
Courts, the Prison Service, Customs and Excise, the Naval 
Service – have the lead roles in reducing illicit drug supply 
throughout the country. Understanding of the roles of these 
agencies, however, varies. Some RDTFs are familiar with the 
national criminal justice policy and legislative frameworks, 
but one observes that it is ‘aware only in general terms’ of 
the services provided. 
The RDTF strategies2 reveal three main approaches to 
addressing supply reduction in the regions:
1.  Facilitating the formation of partnerships between statutory 
and local bodies, for example, supporting closer liaison 
between the Gardaí, Customs and Excise, the fi shing 
community, all seafarers, local authorities and the Naval 
Service, and coastal communities on how they can best 
contribute to the reduction in the traffi cking of drugs; 
and supporting the development of shared initiatives, 
services or protocols between health service providers and 
law enforcement agencies. RDTFs propose measures to 
ensure that effective channels of communication between 
themselves and the gardaí are maintained and enhanced.
2.  Strengthening community participation in supply-
reduction activities through means such as fostering 
estate management programmes in at-risk communities; 
establishing joint policing committees; promoting the 
development of community fora; and encouraging An Garda 
Síochána to engage with community groups to discuss the 
policing plan for the area, including deployment at peak 
times, such as week-ends/closing times. One RDTF observes 
that, ‘dealing effectively with the underlying causes of 
crime and anti-social behaviour will require approaches that 
have a combined focus on the needs of individuals at risk, 
building communities, appropriate community policing, 
and measures to tackle social, economic and educational 
disadvantage. Local policing partnership, properly resourced, 
would allow the Garda to adopt a more pro-active approach 
in aw enforcement and community policing’ (WRDTF: 57). 
3.  Advocating or lobbying for increased resources for policing 
activities in the region, and lobbying for policy changes at 
national level. Possible policy changes include channelling 
confi scated assets derived through drug-dealing to 
communities; extending the Drug Courts model outside 
Dublin; encouraging and supporting the prosecution of 
licensed and off-licence premises and adults when charged 
with supplying alcohol to under-18s; implementing harm-
reduction measures within the criminal justice system; 
considering alternatives to prison; and stronger enforcement 
of existing legislation, e.g. underage drinking laws and 
consistency of court penalties.
One RDTF identifi es a tension between the nationwide role 
of the statutory agencies in intercepting smuggling and 
traffi cking activities, and their regional and local roles in 
interrupting local drug markets:
…the national brief asked of the Customs and An Garda 
Síochána, while essential, may actually be distractive 
to the implementation of initiatives in the context of 
the LDTFs and RDTFs …. The resources available to 
the Customs and Excise and An Garda Síochána are 
insuffi cient to address levels of drugs supply despite 
the very signifi cant hauls of both drugs and alcohol 
at Rosslare and Waterford ports. It is suggested that 
the supply reduction committees of the Regional DTF 
and the Local DTFs are restructured to re-focus supply 
analysis and action at local community level rather than 
national level as at present. (SERDTF: 53) 
A further tension peculiar to the RDTFs is the need to police 
drug markets across urban and suburban areas and rural 
hinterlands, where the market dynamics can alter very 
rapidly. One RDTF notes that drug market activity depends 
on where there is a local Garda station: ‘… it is often the 
case that these rural stations are shared among a wide 
number of small towns and villages and therefore service 
provision is diluted’ (SWRDTF: 35). In another region, the 
consultation process brought forth the observation that 
drugs were being brought into the country through small 
regional fi shing ports, but ‘there was a reluctance to name 
this as it might be detrimental to the image of these places 
and negatively impact on their tourist potential’ (SRDTF: 
59). One RDTF calls for exploration of policing models such 
as the UK Participatory Drugs Profi ling (PDP) model, ‘to 
determine whether such approaches could have benefi ts for 
community policing, supply reduction and crime prevention 
efforts in the rural West of Ireland’ (WRDTF: 57–8), and 
another suggests ‘augmented policing activity which could 
include cross-regional work to tackle middle market supply 
and the strengthening of local policing to disrupt supplies 
on the streets’ (SERDTF: 56). RDTFs operating near active 
centres of drug-related activities, e.g. Dublin or Derry, call 
for special responses. The NWRDTF, operating in close 
proximity to Northern Ireland, and Derry in particular, calls 
for partnerships with cross-border agencies to address illicit 
drug use and underage drinking in the region.
(Brigid Pike)
1. Pike B (2006) RDTF strategies push out the boundaries. 
Drugnet Ireland, Issue 20: 11–12; Pike B (2007) Tools for 
co-ordinating drugs initiatives in the regions. Drugnet 
Ireland, Issue 21: 6–7.
2. The RDTF strategy and action plan documents are held 
in hard copy in the National Documentation Centre, and 
are available online at www.hrb.ie/ndc.
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5Published in the last 12 months, the new social partnership 
agreement,1 national development plan2 and action plan for 
social inclusion3 have all refl ected the emergence of a new 
social inclusion policy framework in Ireland. While not altering 
the direction of drug policy, the new framework has changed 
the way in which the drugs issue is presented. 
In 2001 the Review Group that drafted the 
National Drugs Strategy 2001–2008 welcomed 
the situating of illicit drug policy within the context of social 
inclusion: ‘The Group fully recognises that, notwithstanding 
the obvious benefi ts for communities affected by the 
drugs problem of having a specifi c drugs strategy, the best 
prospects for these communities, in the longer term, rest 
with a social inclusion strategy which delivers 
much improved living standards to areas of disadvantage 
throughout the country.’4 At that time the illicit drugs 
issue was dealt with in social inclusion policy documents 
such as the national development plan 2000–2006, the 
social partnership agreement for 2000–2003 and the 
national anti-poverty strategy, under functional headings 
including healthcare, education and training, regenerating 
disadvantaged communities, tackling homelessness, and 
tackling crime.
In 2005 the National Economic and Social Council (NESC) 
published a report, The developmental welfare state, which 
proposes a new streamlined and comprehensive approach 
to tackling poverty and social exclusion in Ireland.5 
Acknowledging that serious social defi cits remain despite 
Ireland’s economic progress, the NESC report calls for 
a recasting of the social debate in a way that does not 
distinguish between the economic and the social, suggesting 
that this will help to build consensus across the social 
partners, government and wider society. It proposes two 
innovations in the way in which social inclusion interventions 
are presented:
Interventions should be organised according to a  ■
lifecycle framework, comprising four categories – 
children, people of working age, older people, and 
people with disabilities. This arrangement both places 
the individual at the centre of policy making and 
encourages a more joined-up and multi-disciplinary 
approach to policy making.
Greater recognition and weight should be given to the  ■
role of services in providing protection against risks and 
to activist measures, or innovative social policy initiatives, 
in meeting unmet needs and pre-empting problems, as 
opposed to focusing entirely on income transfers. 
In the suite of new social inclusion policy documents 
mentioned in the opening paragraph, the illicit drugs issue 
is now placed within the childhood, youth and people 
of working age stages of the lifecycle framework, and 
interventions are listed under either ‘Services’ or ‘Innovative 
Measures’. Details of the most recent social partnership 
agreement, Towards 2016,1 and the National development 
plan 2007–2012 2 have been described in previous issues of 
Drugnet Ireland.6 In this issue the presentation of the illicit 
drugs issue in the National action plan for social inclusion 2007-
2016 (NAPincl), published in February 2007,3 is described. 
NAPincl includes an additional category – Communities – 
which the NESC report acknowledges as an important source 
of activist or innovative measures. 
Children: NAPincl sets targets for the provision of health 
services for children that include access to treatment for 
100% of problematic drug users aged under 18 years within 
one month of assessment; the introduction of substance 
abuse policies in 100% of schools by 2008; and the use of 
results from various surveys to inform policy making and 
service planning (p. 34). Under the heading of Innovative 
Measures, NAPincl endorses the Young Peoples Facilities 
and Services Fund (YPFSF). It notes that the Fund may be 
extended to other disadvantaged urban areas (p. 37). 
People of working age: Under Services, NAPincl emphasises 
the link between access to a quality health service and 
participation in the social and economic life of society. 
Working to improve the health status of vulnerable groups 
such as those with mental illness, drug users, the homeless 
and Travellers is seen as ‘an essential element of social 
inclusion’. Actions include ensuring that people who are not 
able to meet the cost of GP services for themselves and their 
families are enabled to do so (p. 45).
Communities: Within this category, NAPincl itemises a number 
of Innovative Measures in areas such as arts, sport, and active 
citizenship which are expected to have an impact on the 
illicit drugs issue. NAPincl also lists a series of community-
based programmes which will have an impact on the illicit 
drugs issue, including the Local Development Social Inclusion 
Programme, the Community Development Programme, the 
RAPID Programme, the Community Services Programme, 
Joint Policing Committees, and Family Support Services. The 
National Drugs Strategy is included in this grouping.
(Brigid Pike)
1. Department of the Taoiseach (2006) Towards 2016: ten-year 
framework social partnership agreement 2006–2015. Dublin: 
Stationery Offi ce.
2. Government of Ireland (2007) National development plan 
2007–2013: transforming Ireland – a better quality of life 
for all. Dublin: Stationery Offi ce. 
3. Government of Ireland (2007) National action plan for 
social inclusion 2007–2016. Dublin: Stationery Offi ce.
4. Department of Tourism, Sport and Recreation (2001) 
Building on experience: national drugs strategy 2001–2008. 
Dublin: Stationery Offi ce. Para. 6.1.9.
5. National and Economic Social Council (2005) 
The developmental welfare state. Dublin: NESC
6. Pike B (2006) New social partnership agreement 
addresses drugs and alcohol. Drugnet Ireland, Issue 19: 
7; Pike B (2007) The National Development Plan and the 
drugs issue. Drugnet Ireland, Issue 21: 23–25.
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62008 will see the expiry not only of Ireland’s national drugs 
strategy but also of the United Kingdom’s (UK) drugs strategy 
and the United Nations’ (UN) 10-year action plan on drugs. 
Debate around the future direction of UN drug policy was 
described in the last issue of Drugnet Ireland.1 This article 
describes recent contributions to the debate about UK drug 
policy. Three separate new entities have been formed within 
the civil society sector to kick-start this debate.
In April 2007 the United Kingdom Drug Policy 
Commission (UKDPC) was launched with the release of a 
108-page monograph on UK drug policy.2 Reviewing the 
available evidence, the authors outline the nature of Britain’s 
drug problem, the population pattern of use of various illicit 
drugs, how these patterns have changed over time, and the 
associated harms (including death, health problems, and 
crime). Against this background, they analyse the impact 
of current policies in the areas of enforcement, prevention, 
treatment and harm reduction. They conclude: 
Government policies have only limited impact on rates 
of drug use itself. However, policies are highly relevant 
because they can have signifi cant impact on the levels 
of drug-related harm. …[the government] could make 
better use of available evidence to choose policies that 
more effectively reduce drug-related death, crime, 
physical and mental health problems and other harms to 
the communities that currently suffer the consequences 
of drug use. (pp. 82–3)
The authors call for further research on the consequences of 
drug enforcement efforts, and for the strengthening of the 
Drug Harm Index,3 and more transparent drug budgeting, 
all of which will lead to a greater capacity to measure what is 
currently being spent.
In May 2007 the Drugs and Health Alliance (DHA), a new 
alliance of drug charities, was launched.4 The DHA calls on 
the UK government to put public health, harm reduction 
and tackling poverty and exclusion at the heart of UK drug 
policy. Specifi cally, it calls on the government to:
prioritise public health goals;  ■
implement a truly cross-departmental, public-health-led  ■
strategy and place the lead role in the relevant health 
agencies; 
commission an independent audit of outcomes against  ■
expenditure, comparing public health with criminal 
justice approaches; 
hold an offi cial cross-departmental consultation on the  ■
effi cacy of criminal justice and public health approaches; 
and 
reallocate drug strategy expenditure from criminal justice  ■
to public health. 
The DHA was launched at the RSA (Royal Society for the 
Encouragement of Arts, Manufactures & Commerce) 
on 3 May 2007. Two months previously, the RSA Drug 
Commission on Illegal Drugs, Communities and Public 
Policy published its 300-page report on illegal drugs, 
communities and public policy.5 The RSA Drug Commission 
did not conduct research or hold public hearings but it made 
extensive use of the existing literature, consulted widely 
and took advice from a range of experts in the drugs fi eld. 
Among its many observations and recommendations were the 
following:
Illegal drugs, alcohol, tobacco and other psychoactive  ■
substances should all be brought within a single 
regulatory framework, one capable of treating 
substances according to the amount of harm they cause.
The success of drugs policy should be measured not in  ■
terms of the amount of drugs seized or the number of 
dealers imprisoned but in terms of the amount of harms 
reduced. The fi ght against illegal drugs should not stop, 
but it should be refocused so that it concentrates on 
organised criminal networks.
Drug treatment should be set in a public health  ■
framework that includes both clinical treatment 
and ‘wrap-around’ services such as housing and 
employment. There should be easier access to treatment 
through primary care, and GPs should not be allowed to 
opt out of providing drug treatment.
The Misuse of Drugs Act 1971, now over 30 years old,  ■
should be repealed and replaced by a comprehensive 
Misuse of Substances Act.
(Brigid Pike)
1. Pike B (2007) Civil society joins international debate on 
drug controls. Drugnet Ireland, Issue 22, p. 3:
2. Reuter P and Stevens A (2007) An analysis of UK drug 
policy. A monograph prepared for the UK Drug Policy 
Commission. London: UKDPC. Retrieved 25 July 2007 
from www.ukdpc.org.uk. The UKDPC was established 
to provide independent and objective analysis of drug 
policy and fi nd ways to help the public and policy 
makers better understand the implications and options 
for future policy. Composed of a group of independent 
experts, the UKDPC is chaired by Dame Ruth Runciman. 
3. MacDonald Z, Tinsley L, Collingwood J, Jamieson P and 
Pudney S (2005) Measuring the harm from illegal drugs 
using the Drug Harm Index. Home Offi ce Online Report 
24/05. London: Home Offi ce.
4. For further information on the DHA, visit www.
drugshealthalliance.net. The charities forming the DHA 
include the Beckley Foundation, the International Harm 
Reduction Association, the Kaleidoscope Project, Release, 
Transform Drug Policy Foundation and the UK Harm 
Reduction Alliance.
5. RSA Commission on Illegal Drugs (2007) Drugs – 
facing facts. The report of the RSA Commission on Illegal 
Drugs,Communities and Public Policy. London: RSA 
Commission on Illegal Drugs. Retrieved 25 July 2007 
from www.rsadrugscommission.org. The Commission 
was appointed in January 2005 as an independent body 
under the auspices of the RSA. Its members were drawn 
from various fi elds and disciplines in the drugs area, and 
also from business, local government, health and social 
services, parliament, the professions and academia.
Civil society calls for new directions for 
UK drug policy
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7The Merchants Quay Ireland (MQI) annual review for 2006, and its re-designed website, were 
launched by Minister of State with responsibility for the National Drugs Strategy Mr Pat Carey TD 
on 31 August 2007.1 The Minister spoke of the growing need for needle exchange services to be 
made available nationally. 
More than 39,460 visits were recorded at MQI’s needle-exchange service, of which 1,754 were by 
new clients. While the majority were heroin users, 20% were also using cocaine. Chief executive 
Mr Tony Geoghegan said that people tended to inject drugs for a year or more before they 
sought treatment and that during this period they were at risk of contracting hepatitis C or HIV. 
He highlighted the lack of localised harm-reduction services, saying that, while media attention 
had focused on problem cocaine use, heroin remained a major issue throughout the country.
The review also highlights the increasing demand for MQI’s homeless services, particularly from 
people from the new EU member states. By October 2006 over 50 eastern Europeans were 
availing of the services every day. MQI has produced information leafl ets in Polish and Russian 
(available on the new MQI website), and some staff have taken language classes. Mr Geoghegan called for some relaxation of 
the Habitual Residence Condition to allow non-nationals greater access to social welfare services. 
The types of service offered by MQI and the numbers of people accessing them in 2006 are shown below.
Service Type of intervention No. of participants Outcomes
Needle exchange 
and health 
promotion services
Promoting safer injecting techniques 
HIV and hepatitis prevention
Safe sex advice
Information on overdose
39,460 (including 
1,754 new clients)
308 safer injecting 
workshops
Not available
Stabilisation services Methadone substitution
Supportive day programmes
Gateway programme
Counselling
30
18
16 (monthly 
average)
Not available
Not available
Not available
Not available
Not available
Settlement service Assist service users to access interim and long-term 
accommodation
An average of 52 a 
month
An average of 25 
a month availed 
of the Tenancy 
Sustainment Service 
Integration 
programmes
Access to transitional accommodation (Ballymount 
House) for up to 24 weeks 
Group and one-to-one therapeutic sessions
6 Not available
Training and work 
programmes
FÁS Community Employment scheme 130 70 secured 
permanent 
employment or 
moved to further 
education
Catering training programme 21 10 awarded FETAC 
Certifi cate
High Park 17-week, drug-free residential programme including 
individual counselling, group therapy, educational 
groups, work assignments and recreational activities
73 (of whom 27 
were admitted for 
detoxifi cation)
19 completed detox 
St Francis Farm Therapeutic facility offering a 6–12-month programme 30 17 completed three 
months or more
(Vivion McGuire)
1. Merchants Quay Ireland (2007) Annual review 2006. Dublin: MQI.
MQI annual review 2006
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From left: Fergus McCabe, community worker and former community sector representative on 
the National Drugs Strategy Team, and David Connolly, chair of the Ballyfermot LDTF, at the MQI 
launch (photo: Jim Berkeley)
Along with its annual review, Merchants Quay 
Ireland launched its re-designed website (www.
mqi.ie). MQI has had an online presence for some 
years but the new site is a signifi cant development 
in terms of design, content, navigation and 
accessibility. The site is rich in content that is clearly 
and logically organised; all parts of the site are 
within the maximum ‘3 clicks’ recommended in 
contemporary web design. Navigation is further 
aided by the high level of consistency in navigation 
devices, font styles and headings, colour and page 
structure across all parts of the site.
Photos of anonymous fi gures in various parts of 
Dublin used as background to the main pages work 
well aesthetically and refl ect the nature of the site’s 
content. Thumbnails of these portraits are used to 
form an alternative menu on the home page, which 
has the effect of softening an otherwise busy and 
content-heavy page. Images are used to highlight 
both the news stories and items selected for display 
on the front page, which reduces the crowding and 
noise often found on sites that use contemporary 
content-management systems.
The website’s contents menu neatly delineates the 
various aspects of MQI’s work.  The organisation’s 
extensive and diverse research output over the 
past ten years is available to download and 
the research page also contains links to many 
other organisations’ publications on drugs and 
homelessness. The site also has a short guide to 
MQI services in Polish and Russian translation. 
The Media page is a very useful source of concise 
factual information on drug use, homelessness and 
the work of MQI for those who need information 
quickly and who may not be familiar with these 
subjects.
The new MQI website is an impressive addition to 
the growing collection of online resources available 
to those interested in the drugs area. It manages to 
present a considerable amount of documentation 
and other information in an attractive and easily-
navigable resource.
(Brian Galvin)
The new MQI website
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9The Research Outcome Study in Ireland (ROSIE) is 
a national multi-site drug treatment outcome study 
which is being conducted by a team at the National 
University of Ireland, Maynooth, on behalf of the 
National Advisory Committee on Drugs (NACD). 
The aim of the study is to recruit and follow opiate 
users entering treatment and to document their 
progress after six months, one year and three years.
At baseline, the study recruited 404 opiate users 
aged 18 years or over entering treatment or, in the 
case of a sub-sample of 26 (6%), attending needle-
exchange services. The participants were engaged 
in one of three different forms of treatment: 
methadone maintenance/reduction (53%, 
n=215), structured detoxifi cation (20%, n=81) and 
abstinence-based treatment (20%, n=82).
The treatment outcomes presented in the fi rst 
three papers in the ROSIE Findings series have been 
reported in previous issues of Drugnet Ireland. The 
fourth paper in the series, ROSIE Findings 4,1 provides 
a summary of the outcomes for people in the 
methadone modality one year after treatment intake. 
The provision of methadone, a long-acting opiate 
agonist, under medical supervision is the main 
pharmacological substitution intervention for opiate 
users in Ireland. Initially, a low commencing dose 
(usually 10–40 ml) is prescribed, aimed at achieving 
a level of comfort while reducing the likelihood of 
overdose. By the end of six weeks’ treatment, the 
individual is usually stabilised on an appropriate 
therapeutic dose. Methadone maintenance is a 
long-term treatment option of no fi xed duration 
and there are different models of maintenance 
prescribing, ranging from highly structured regimes 
to low-threshold programmes.
The ROSIE study methadone cohort (n=215) was 
recruited from health board clinics (50%, n=108), 
general practitioners (25%, n=54), community-
based clinics (22%, n=48) and prison (2%, n=5). 
The analysis presented in Findings 4 is based on the 
167 (78%) participants who provided valid answers 
to each individual question during their treatment 
intake and one-year follow-up interviews.
Participants in the methadone modality were 
typically male (68%), with an average age of 28 
years, and were largely dependent on social welfare 
payments (81%). The majority (64%) had children 
aged under 18 years. Sixty per cent had spent time 
in prison and 17% had been homeless in the 90 
days prior to treatment intake interview. 
Treatment completion rates
Methadone is a long-term treatment option and, 
at one year, 3% (n=5) had completed treatment. 
The retention rate was high: 79% (n=132) were still 
receiving methadone treatment at one year, 6% 
(n=10) had transferred to another treatment modality 
and 12% (n=20) had dropped out of treatment. 
One year after treatment intake, 90% (n=151) 
reported being in some form of drug treatment. 
Eighty-four per cent (n=141) were in methadone 
treatment, 26% (n=44) were attending one-
to-one counselling, 15% (n=25) were in group 
work (Narcotics Anonymous meetings, aftercare 
programmes, and Community Employment 
schemes), and 1% (n=2) were in a structured 
detoxifi cation programme.
Drug use outcomes
The number of participants who reported using 
heroin, non-prescribed methadone, non-prescribed 
benzodiazepines, cocaine powder or crack cocaine 
in the 90 days prior to interview decreased between 
treatment intake and one-year follow-up. The most 
substantial reduction was in opiate use (heroin and 
non-prescribed methadone) both in terms of the 
proportion of participants using the drug and the 
frequency of use. Heroin use decreased from 84% at 
treatment intake to 53% at one year, while non-
prescribed methadone use decreased from 48% to 
16%. The frequency of heroin use decreased from 50 
days out of 90 at treatment intake to 15 days out of 
90 at one year, while the frequency of non-prescribed 
methadone use decreased from 16 days out of 90 at 
treatment intake to 4 days out of 90 at one year. 
Polydrug use in the 90 days prior to interview also 
reduced, from 78% (n=131) at treatment intake to 
56% (n=94) at one year. At one-year follow-up, 16% 
(n=27) of participants reported that they had not 
used any illicit drugs in the 90 days prior to interview. 
Crime outcomes
Overall, the proportion of participants who 
reported involvement in crime had decreased 
from 49% at treatment intake to 27% at one 
year. There was a reduction in the percentage of 
participants involved in acquisitive crime, from 28% 
at treatment intake to 15% at one year. 
Risk behaviour outcomes
There was a signifi cant reduction in the number of 
participants who reported injecting drug use. At 
treatment intake, 44% (n=73) had injected a drug 
in the 90 days prior to interview, compared with 
32% (n=53) at one year. There were no changes in 
participants’ injecting-related risk behaviours. There 
was a non-signifi cant reduction in the proportion 
of participants who reported an overdose in the 
90 days prior to interview, from 8% (n=12) at 
treatment intake to 6% (n=9) at one year.
Health outcomes
Ten symptoms were used to measure the physical 
health of participants (see paper for details). The 
number of participants who reported nine of the 
ten physical health symptoms increased between 
treatment intake and one year, with a signifi cant 
increase observed in the proportion reporting 
stomach pains.
Ten symptoms were also used to measure the 
mental health of participants (see paper for details). 
There was an increase in the number of participants 
who reported suffering from any six of the ten 
mental health symptoms.
ROSIE Findings 4: summary of 
methadone treatment outcomes
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In 2004, the National Drugs Strategy Team funded 
Merchants Quay Ireland to co-ordinate training programmes 
for two levels of service providers who come in contact 
with cocaine users – front-line staff and key or case workers 
supporting active cocaine users. The training programme 
outlined in the table below was implemented in May 2005. 
Wendy Crampton1 evaluated the training, using: 
participant self-assessment and evaluation ■
tutor evaluation  ■
participant follow-up questionnaire ■
work supervisors’ feedback.  ■
The evaluation of the level-one course indicated that the 
participants’ level of knowledge had increased considerably, 
from an average of 50% per participant to 80%. While each 
individual’s knowledge about cocaine increased during 
the course, many wanted more knowledge and practical 
experience with clients. Participants rated the course content 
at 79%, the training style at 85% and the venue at 81%. 
The trainer rated two of the three groups of participants as 
having beginner-level knowledge and one group as having 
medium level. The trainer noted that the participants were 
open to learning, asked lots of questions and were willing to 
share their knowledge. 
Because of issues that arose during Course 1 of the level-
two course, some adjustments were made to the plans for 
Course 2, and the two courses were evaluated separately. 
The evaluation of Course 1 indicated that the participants’ 
level of knowledge had increased by 33%, from an average 
of 58% per participant to 77%. Participants rated the course 
content at 64%, the training style at 67% and the venue 
at 57%. The trainer reported that some participants were 
inexperienced and this resulted in ‘lecture style’ training. 
Based on this and other feedback from Course 1, MQI 
requested that the tutor introduce interactive training 
methods in Course 2. They also changed the training venue 
and requested a list of participants in advance of the course. 
The evaluation of the level-two Course 2 indicated that the 
participants’ level of knowledge increased by 43%, from an 
average of 59% per participant to 84%. Participants rated 
the course content at 78%, the training style at 86% and the 
venue at 78%. The feedback from Course 2 was positive and 
demonstrated that it is important to learn from participants’ 
evaluations.
(Jean Long)
1. Crampton W (2005) An evaluation of a cocaine training 
programme. Dublin: Merchants Quay Ireland. Available 
on the National Drugs Strategy page at www.pobail.ie.
Training type Target 
group
Trainers Expected learning outcomes Number of 
attendees
A one-day, level-one 
course, run for three 
separate groups
Providing basic 
knowledge of cocaine and 
related issues and skills to 
support cocaine users
Front line 
staff and 
agencies
Piper Projects:
same facilitator 
for each of the 
three groups
Know:
facts about cocaine, dopamine and  ■
adrenaline
methods of cocaine consumption ■
effects of polydrug use ■
trigger factors associated with cocaine use ■
signs and symptoms of cocaine use ■
role of and types of harm reduction and  ■
complementary therapy
Skills to support cocaine users
Expected: 60
Attended: 55
Completed: 53
A three-day, level- two 
course, run for two 
separate groups (Course 1 
and Course 2)
Providing basic 
assessment and 
motivational counselling 
techniques to support 
cocaine users through 
treatment
Key or case 
workers
Piper Projects:
different 
facilitator for each 
of the two groups
Know:
facts about cocaine ■
about motivation and the wheel of  ■
change
appropriate treatment interventions ■
risks and benefi ts of interventions ■
how to prevent relapse ■
Ability to:
identify signs and symptoms of cocaine  ■
use
assess client needs ■
develop care plans ■
counsel using motivational interviewing ■
Expected: 40
Attended: 49
Course 1 – 24
Course 2 – 25
Completed: 38
Course 1 – 20
Course 2 - 18
Evaluation of a cocaine training programme
Service contact
ROSIE Findings 4 reports an increase in participants’ contact 
with GPs, employment/education services and housing/
homeless services. 
The authors state that the fi ndings presented in this paper 
demonstrate that retention in methadone treatment 
is high, and continued participation in a methadone 
programme substantially reduces opiate use, injecting 
drug use and involvement in crime. The outcomes for 
ROSIE participants in the methadone modality compare 
favourably with international outcome studies. Although 
rates of improvement in physical and mental health were 
disappointing, it is hoped that results from the ROSIE three-
year follow-up will provide evidence of a positive association 
between long-term treatment and improvements in physical 
and mental health.
(Deirdre Mongan)
1. Cox G, Comiskey C and Kelly P (2007) ROSIE Findings 4: 
summary of 1-year outcomes: methadone modality. Dublin: 
National Advisory Committee on Drugs. Available at 
http://www.nacd.ie/publications/treatment_rosie4.html 
ROSIE Findings 4 (continued)
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Cocaine Response: Sharing Good Practice, a conference 
hosted by SAOL and the National Drugs Strategy Team 
(NDST) and attended by 280 delegates, was held in Croke 
Park, Dublin, on 28 June 2007. The aim of the conference 
was to further collaboration and knowledge sharing 
between the various agencies involved in the fi eld of 
cocaine intervention and good practice. A consistent theme 
throughout the conference was that progress depended 
on continued co-operation and partnership between 
community and voluntary services and statutory agencies. 
Minister of State with responsibility for drugs strategy, 
Mr Pat Carey TD, opened the conference. The Minister 
acknowledged that cocaine presented a serious issue for 
communities and drug services throughout the country 
and that an effective response needed continued planning 
and proper resources. He welcomed SAOL’s initiative in 
developing a resource pack and organising the conference. 
These were examples, he said, of the important contribution 
that the community and voluntary sector makes in the area 
of problem drug use. He said that he strongly believed 
that treatment, particularly in the form of counselling, 
can and does work, and he noted the commitment to 
cocaine-specifi c clinics in the section on drugs in the new 
Programme for Government. 
Two recurring themes were the dangers of cocaine use and 
the value of partnership as an approach to dealing with 
drug problems. Patricia O’Connor, director of the National 
Drugs Strategy Team (NDST), emphasised both of these 
points. She stressed that cocaine use can, and often does, 
result in signifi cant health problems and death. In view of 
these risks, the challenge is to get this message across to 
all age groups, all sections of the workforce and to those 
communities already most affected by heroin use. She 
appealed to the media to play a supportive role in this task 
and to keep publicising the risks. Joan Byrne, director of 
the SAOL project, spoke of the challenge facing services in 
turning a predominantly opiate-focused treatment system 
into one that meets the needs of cocaine and polydrug 
users. She emphasised the importance of information on 
drug trends and noted the limited role that the experience 
of local communities has in informing offi cial drug policy. 
She praised the work and the partnership approach of the 
NDST.
The conference also heard an overview of the recent NACD 
cocaine report presented by Mairead Lyons, NACD director. 
Siobhán Cafferty outlined the tools which comprise the 
Cocaine Resource Pack: a CD for low-threshold, chaotic 
users who are unable to commit to attending a project on a 
regular basis; Relapse Worksheets, for those who can attend 
projects or services on a more regular basis and who have 
an established relationship with a key worker; and Reduce 
the Use, a booklet for those in the contemplation stage 
who are linked in with a project/service on a more regular 
basis. Tony Duffi n of the Ana Liffey Drug Project described a 
new, joint community/statutory harm reduction campaign 
targeting injecting cocaine users. The conference also heard 
a report from the HSE on plans for addressing cocaine use 
and examples of effective responses in Tallaght with a client 
group not traditionally engaged with drug services. The 
role of holistic treatments in dealing with problem drug use 
was described, and was a theme of one of the conference 
workshops.
(Brian Galvin)
Copies of the report on the conference are available from 
SAOL. Contact progressionroutes@saolproject.ie.
Conference on cocaine intervention and 
rehabilitation
Anna Quigley of CityWide speaking at the cocaine 
conference (photo: Progression Routes)
Siobhán Cafferty of SAOL talking about their Reduce 
the Use programme at the cocaine conference (photo: 
Jim Berkeley)
Mr Pat Carey TD, Minister of State with special 
responsibility for drugs strategy and community 
affairs, speaking with Tony Geoghegan of MQI at the 
cocaine conference (photo: Jim Berkeley)
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Data used in the following analysis were extracted 
from the database of the Hospital In-Patient Enquiry 
(HIPE) scheme maintained by the Economic and 
Social Research Institute.1 HIPE is a computer-
based health information system designed to 
collect medical and administrative data regarding 
discharges and deaths from acute hospitals.2 Each 
HIPE discharge record represents one episode of 
care; each discharge of a patient, whether from the 
same or a different hospital, or with the same or 
a different diagnosis, gives rise to a separate HIPE 
record. The records therefore facilitate analyses 
of hospital activity rather than of the incidence of 
disease. HIPE does not record information on cases 
that attend accident and emergency units but are 
not admitted as inpatients. 
Number of deaths from overdose
The total number of overdose cases for the period 
1996 to 2004 inclusive was 46,539. Eighty of 
these cases died and have been excluded from this 
analysis.
Age group
Cases aged between 15 and 65 years inclusive are 
included in this analysis. Figure 1 shows that the 
20–24-year age group is at highest risk, with the 
incidence of overdose decreasing with age. It is 
important to note the signifi cant number of cases 
in the 15–19-year age group.
Area of residence
From 1999 to 2001 a steady increase in overdose 
cases was recorded among persons resident outside 
Dublin. In 2002 there was a slight decrease among 
this population, followed by an increase in 2003 
and then a signifi cant decrease (18%) in 2004. 
Reported overdose cases among persons resident in 
Dublin decreased steadily between 2000 and 2004.
Overdose data from the HIPE 
scheme
Figure 1 Incidence of overdose by age group, 1996 to 2004
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Most common drug category by type of 
overdose
Attempted suicide accounted from the majority 
(81%) of overdose cases reported through HIPE 
for the years 1996 to 2004 inclusive. Of these 
cases, 42% related to the use of a tranquilliser or 
other psychotropic-type drug and 39% related to 
intentional overdose with analgesics. According to 
the 2005 annual report of the National Registry of 
Deliberate Self Harm, 41% of all drug overdoses 
involved a minor tranquilliser, 32% involved 
paracetamol and 23% involved anti-depressants.2 
Figure 2 Area of residence of overdose cases, 1996 to 2004
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Gender
There were more overdose cases among females 
than among males. A signifi cant decrease in 
reported incidence of overdose among females 
(17%) and among males (15%) is evident between 
2003 and 2004.
Opiates
Opiate-type drugs were involved in less than 1% 
of cases reported for each year between 1996 and 
2004. Since 2002, the trend in accidental poisoning 
by opiates other than heroin has stabilised. The 
number of cases of accidental poisoning by heroin 
decreased by 58% in the same period, from 19 in 
2002 to 8 in 2004.
Overdose data (continued)
Figure 3 Most common drug category, by type of overdose, 1996 to 2004 
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Figure 4 Incidence of overdose by gender, 1996 to 2004
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Figure 5 Incidence of overdose involving opiate-type drugs, 1996 to 2004
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Thirteen per cent more males than females overdosed 
using opiate-type drugs during the period 1996 to 2004. 
A signifi cant number (16%) of those who overdosed using 
opiate-type drugs were in the 15–19-year-old group; 
however, the majority (27%) were in the 20–24-year-old 
group, and the incidence decreased in successive age groups 
between 25 and 54 years. Thirty-eight per cent of overdose 
cases involving an opiate-type drug occurred in the Dublin 
region.
(Ena Lynn)
1. I would like to thank the ESRI for providing the data for 
the analysis included in this article.
2. The coding scheme used to code diagnoses for the 
years presented in this analysis was the International 
Classifi cation of Diseases, 9th Revision, Clinical 
Modifi cation, known as ICD-9-CM. Further information 
and reports on HIPE can be found on the Economic and 
Social Research Institute website at www.esri.ie 
3. National Registry of Deliberate Self Harm Ireland (2005) 
Annual report 2005. Cork: National Suicide Research 
Foundation.
A study which aimed ‘to explore drug users’ experiences and 
perspectives of overdose’ was carried out in Dublin in 2006.1 
The main objectives were to investigate drug users’ personal 
perspectives and experiences of overdose, their experiences 
of witnessed overdoses, and their views on possible 
strategies to prevent or reduce the incidence of overdoses.
The inclusion criteria were as follows: all participants in the 
study must be receiving methadone maintenance therapy 
in the Drug Treatment Centre Board for treatment of opiate 
addiction, all participants must have overdosed in the 
preceding year, all participants must have voluntarily agreed 
to participate in the study and signed a consent form, and 
all participants must be fl uent in English. A convenience 
sampling method was used and the fi rst 10 participants who 
volunteered and met the inclusion criteria were selected 
to take part in in-depth semi-structured interviews, which 
lasted between 30 and 60 minutes. Participants ranged in 
age from 22 to 46 years; seven were male and three were 
female. All 10 had hepatitis C and four had HIV. 
The researcher asked participants questions about their 
own overdose experiences, including: what drugs they had 
used; their method of drug taking; their actual experience 
of overdose; whether the overdose was accidental or 
intentional; their perceived reasons and/or precipitating 
factors for accidental overdose; trigger factors for intentional 
overdose; their knowledge of medical treatment for 
overdose; and possible strategies to prevent or reduce future 
overdoses. 
The numbers of personal overdoses among the participants 
ranged from two to 30. The most recent overdose was 
accidental in six cases and intentional in four cases. All 
10 had engaged in polydrug use in their most recent 
overdose. Five of the six participants who had accidentally 
overdosed had used heroin, and one of the four who 
had intentionally overdosed had used heroin. The most 
common drug used was methadone and all 10 participants 
had consumed methadone in their most recent overdose. 
Three of the participants reported intentionally overdosing 
on a combination of prescribed methadone and other 
prescription medication. Trigger factors for intentional 
overdoses included sexual abuse, physical abuse, depression 
and recent bereavement. Perceived reasons for accidental 
overdoses included reduced tolerance to drugs following a 
period of abstinence, variation in the quantity and quality of 
heroin used, and polydrug use, especially of benzodiazepines 
or alcohol in conjunction with heroin. Four participants were 
hospitalised as a result of their most recent overdose (two 
from intentional overdoses, two from accidental overdoses). 
Participants showed a lack of knowledge about medical 
treatment of overdose. Those hospitalised did not know how 
they had been treated, and only one of the 10 participants 
was able to name the heroin antidote given to overdose 
victims. 
All 10 participants had witnessed another person overdosing. 
They were questioned about their knowledge of overdose 
intervention, how they had intervened and, if they had not 
done so, why they had not. Interventions such as slapping 
the victim, walking them around, dousing them with water, 
using mouth-to-mouth resuscitation and placing them in the 
recovery position were implemented before an ambulance 
was called. In general, an ambulance was called only in 
cases where there was serious danger, and only then after a 
delay of at least 10 minutes. In cases where the participants 
witnessed an overdose and did not intervene, the most 
common reason given was fear of police involvement. 
Participants were asked whether they thought training in 
overdose prevention should be available to drug users. All 
10 agreed that such training should be available to all drug 
users and two stated that it should be made compulsory. 
The study makes a number of recommendations for 
reducing drug overdoses and deaths:
a training programme on drug overdose prevention  ■
tighter legislation and caution when prescribing  ■
medication to drug users
improvements in initial and ongoing psychiatric  ■
assessment of drug users
frequent drug analysis screening of street heroin ■
decreased police presence at overdose situations ■
pilot studies on naloxone distribution among peers ■
supervised drug injecting facilities. ■
(Lorraine Coleman and Ena Lynn)
1. Bolger A (2007) Drug users’ experiences and 
perspectives of overdose: an exploratory study. MSc 
thesis submitted to Dublin City University.
Overdose data (continued)
Drug users’ experiences of overdose
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HIV (subsequently known as HIV1) was identifi ed 
in 1981 and HIV2 was identifi ed in 1986. The 
virus attaches itself to the CD4 particle of the 
T-lymphocytes. These T-lymphocytes co-ordinate 
the body’s immune response. HIV may lead to a 
condition known as acquired immunodefi ciency 
syndrome (AIDS). This condition generally occurs 
when the CD4 count is below 200 per millilitre and 
is characterised by the appearance of opportunistic 
infections. Such infections take advantage of a 
weakened immune system. The HIV virus is found 
in all body fl uids and is transmitted via sexual 
intercourse (both heterosexual and homosexual), 
mother to foetus and baby, infected blood and 
blood products and procedures with unsterile 
needles, syringes and skin-piercing instruments. 
Best evidence available to date indicates that once 
an individual is infected he or she remains infected 
for life. 
Voluntary linked testing for antibodies to HIV has 
been available in Ireland since 1985. According 
to the most recent report of the Health Protection 
Surveillance Centre (HPSC), at the end of 2006 
there were 4,419 diagnosed HIV cases in Ireland, of 
which 1,327 (30%) were probably infected through 
injecting drug use.1 
Figure 1 presents the number of new cases of HIV 
among injecting drug users, by year of diagnosis, 
reported in Ireland; data from 1982 to 1985 were 
excluded from the fi gure as these four years were 
combined in the source records. Figure 1 is based 
on data reported to the Department of Health and 
Children, the National Disease Surveillance Centre 
and its successor, the HPSC. There was a fall in the 
number of HIV cases among injecting drug users 
between 1994 and 1998, with about 20 cases per 
year compared to about 50 cases each year in the 
preceding six years. In 1999, there was a sharp 
increase in the number of cases among injecting 
drug users, which continued into 2000, with 69 
and 83 new cases respectively. Between 2001 and 
2003 there was a decline in the number of new 
injector cases (38, 50 and 49 respectively) when 
compared to 2000 but the number was higher than 
in 1998. In 2004, once again, there was an increase 
(to 71 cases) in the number infected through 
injecting drug use compared to the preceding three 
years. In 2006 there were 57 cases infected through 
injecting drug use. It was diffi cult to interpret 
the trend due to the relatively small numbers 
diagnosed each year, so a smoother curve (red 
plot line in Figure 1) was calculated using a rolling 
centred three-year average. This curve presents an 
increase in the annual number of HIV cases in 1999; 
this higher number of cases was sustained between 
2000 and 2006. This indicates a true increase in the 
number of cases. 
Of the 57 new HIV cases among injecting drug 
users reported to the HPSC in 2006, 41 were male 
and 16 were female and the average age was 32 
years. Of the 39 cases for whom place of residence 
was known, 37 lived in the HSE Eastern Region. 
This HPSC report confi rms the need, emphasised 
by the authors of the report on the 2004 data, to 
continue to promote the use of harm reduction 
measures among injecting drug users.
(Jean Long)
1. Health Protection Surveillance Centre (2007) 
Newly diagnosed HIV infections in Ireland: 
quarters 3 & 4 2006, and 2006 annual summary. 
Dublin: Health Service Executive. 
2. Long J (2006) Blood-borne viral infections among 
injecting drug users in Ireland, 1995 to 2005. 
Overview 4. Dublin: Health Research Board.
New data on the incidence of HIV
Figure 1 Actual number and rolling average number of new cases of HIV among injecting drug 
users, by year of diagnosis, reported in Ireland, 1986 to 2006
Source: Long (2006)2
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Until 2006, the principal source of information on 
drug offences was the annual reports of the Garda 
Síochána. In 2006, responsibility for reporting crime 
statistics was transferred to the Central Statistics 
Offi ce (CSO). The CSO has published some data 
on drug offences and drug seizures on a Garda 
divisional basis; more detailed data will be made 
available once the Garda data have been fully 
examined (CSO, personal communication, 2007).
The vast majority of drug offences reported come 
under one of three sections of the Misuse of Drugs 
Act (MDA) 1977: section 3 – possession of any 
controlled drug without due authorisation (simple 
possession); section 15 – possession of a controlled 
drug for the purpose of unlawful sale or supply 
(possession for sale or supply); and section 21 – 
obstructing the lawful exercise of a power conferred 
by the Act (obstruction). Other MDA offences 
regularly reported on relate to the unlawful 
importation into the State of controlled drugs 
contrary to section 21; permitting one’s premises to 
be used for drug supply or use contrary to section 
19; the use of forged prescriptions (section 18); and 
the cultivation of cannabis plants (section 17). 
Figure 1 shows trends in the numbers of drug 
supply, possession and total drug offence 
prosecutions between 2000 and 2006. The majority 
of prosecutions are for drug possession, which have 
risen steadily since 2003 and accounted for 73.2% 
of the total drug offences prosecuted in 2006. The 
number of simple possession offences increased 
from 7,432 in 2005 to 8,556 in 2006. The number 
of supply offences leading to a prosecution in 
2006 was 2,525, representing 21.6 % of the total 
number of offences prosecuted.
Figure 2 shows trends in prosecutions for a 
selection of other offences where proceedings 
commenced between 2000 and 2006. Prosecutions 
for obstruction increased by 704% between 2000 
and 2005, and decreased from 479 in 2005 to 373 
in 2006. Prosecutions for cultivation or manufacture 
of drugs increased by 200% between 2005 and 
2006.
Drug-crime statistics
Figure 1 Trends in possession (s.3 MDA), supply (s.15 MDA) and total drug offence prosecutions, 
2000–2006 
Source: Annual reports of An Garda Síochána 2000–2005; Central Statistics Offi ce 2006
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Figure 2 Selected MDA offences, excluding possession and supply, where proceedings 
commenced, 2000–2006
Source: Annual reports of An Garda Síochána, 2000–2005; Central Statistics Offi ce 2006
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With regard to the importation and internal 
distribution of drugs – the middle market – data 
on drug supply offence prosecutions by Garda 
division are a possible indicator of distribution 
patterns.1 While these data primarily refl ect law 
enforcement activities and the relative ease of 
detection of different drugs, they may also provide 
an indicator of national drug distribution trends 
and whether, for example, there is a concentration 
of prosecutions along traffi cking routes. Figure 3 
shows the number of prosecutions for drug supply 
offences in Garda regions outside the Dublin 
Metropolitan Region (DMR).
The upward trend since 2004 in prosecutions for 
drug supply continued in 2006 (Figures 3 and 4). 
Although the majority of such prosecutions still 
take place in the DMR, the proportion of the total 
number which take place outside the DMR has 
increased since 2004 (Figure 4). 
Although the number of drug seizures in any 
given period can be affected by such factors as law 
enforcement resources, strategies and priorities, 
and by the vulnerability of traffi ckers to law 
enforcement activities, drug seizures are considered 
as indirect indicators of the supply and availability 
of drugs. Data presented below on trends in the 
number of drugs seized by drug type are derived 
from the annual reports of An Garda Síochána, 
which has retained responsibility for reporting this 
specifi c data.
Cannabis seizures account for the majority of all 
drugs seized. Of the 7,550 reported drug seizures 
in 2006, 3,853 (51%) were cannabis-related. 
Figure 5 shows trends in seizures of a number of 
selected drugs, excluding cannabis, between 2000 
and 2006. We can see a continuous steady rise in 
cocaine seizures and a sharp rise in heroin seizures, 
from 725 in 2005 to 1,115 in 2006. The number 
of seizures of ecstasy-type substances also rose in 
2006, following a steady decline since 2000.
(Johnny Connolly)
1. Connolly J (2005) The illicit drug market in 
Ireland. Overview 2. Dublin: Health Research 
Board.
Drug-crime statistics (continued)
Figure 3 Drug supply (s.15 MDA) offences outside the DMR where criminal proceedings 
commenced, 2000–2006
Source: Annual reports of An Garda Síochána 2000–2005; CSO, personal communication, 
July 2006
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Drug-crime statistics (continued)
Figure 5 Trends in the number of seizures of selected drugs, excluding cannabis, 2000–2006
Source: Annual reports of An Garda Síochána 2000–2006
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On 25 May 2007 the World Health Organization 
regional offi ce in Europe published Health in prisons, 
a guide for the provision of health care in prisons.1 
The guide outlines steps that prison services can 
take to reduce public health risks associated with 
compulsory detention and outlines internationally 
recommended standards for prison health. The 
authors provide guidelines on assessing prisoner 
needs and providing evidence-based prevention, 
care and treatment in the prison setting. A number 
of chapters are of interest to those working in 
the drugs area, such as ‘drug use and services 
in prisons’, ‘substitution treatment in prisons’, 
‘communicable diseases’ and ‘HIV infection and 
human rights in prisons’. This article highlights 
the steps recommended to deal with drug-related 
issues and infectious diseases. 
Survey estimates indicate that half of the prisoners 
in the EU have used drugs and that many are 
problematic and/or injecting drug users. A number 
of European surveys indicate that the prevalence 
of blood-borne viral infections such as hepatitis B, 
hepatitis C and HIV is higher among prisoners than 
among the general population. Drug use is one of 
the main problems facing prison services; it leads to 
problems between prisoners themselves, between 
prisoners and their relatives and between prisoners 
and prison staff. The WHO guide emphasises that 
a wide range of drug services is required within 
prisons in order to deal with the demand for drugs. 
These services need to be linked with community 
drug services in order to ensure continued 
treatment on entry to prison and on release. Prison 
services need to ensure that measures to address 
the high risk of fatal overdose on release from 
prison are implemented. Prison-based drug services 
should participate in drug treatment monitoring 
systems and drug service evaluations. 
According to the WHO guide, opiate substitution 
is part of generic drug treatment services and is 
the gold standard for the management of opiate-
dependent individuals. Methadone (or other 
substitution) treatment reduces the incidence of 
injecting drug use and HIV. Participation in opiate 
substitution treatment reduces the incidence of 
crime and the number of admissions to prison. In 
Europe, the most common form of substitution 
treatment is methadone. The number receiving 
opiate substitution treatment has increased 
substantially within the past 10 years. Continuity 
of methadone is required between community 
drug treatment services and prison services. 
Before methadone substitution is started in prison, 
participants must be provided with information 
about its interaction with other medications, risks 
associated with multiple drug use and risk of opiate 
and polydrug use overdose. 
The infectious disease status of prisoners 
(particularly in relation to HIV) is confi dential 
information and those with access to such 
information should respect this principle. All prisons 
should have easy access to confi dential voluntary 
testing facilities so that early diagnosis and 
intervention are encouraged. 
The authors report that the spread of blood-
borne viral infections can be reduced through 
implementing universal precautions, a combination 
of discouraging tattooing and providing sterile 
tattooing services, as well as a combination of drug 
treatment services and needle exchange services. 
In general, prison services should encourage 
external support for those with mental illness, 
substance misuse and long-term infectious diseases.
(Jean Long)
1. Moller L, Stover H, Jurgens R, Gatherer A and 
Nikogosian H (2007) Health in prisons: a WHO 
guide to essentials in prison health. Copenhagen: 
World Health Organization.
A World Health Organization guide 
to health in prisons
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Emotional intelligence, mental health and juvenile 
delinquency,1 the report of a study by Hayes 
and O’Reilly, was presented at an international 
conference at University College Dublin on 18 
May 2007. Researchers interviewed three groups 
of adolescent males (average age 14.9 years): 30 
participants were residing in juvenile detention 
schools (the offender group), 20 had been referred 
to an adolescent mental health service in HSE 
South (the mental health group), and 30 were 
recruited from a secondary school in County 
Cork (the control group). They used a number of 
validated instruments to determine each child’s 
emotional intelligence and mental well-being, and 
obtained demographic characteristics and history of 
offending by means of a questionnaire.
The fi ndings show that children in detention 
schools in Ireland experience very high rates of 
substance dependence and psychiatric disorder, 
engage in serious criminal behaviour and have 
signifi cant defi cits in emotional intelligence and 
cognitive ability. 
Eight out of ten (83%) of the offender group met 
diagnostic criteria for at least one psychological 
disorder, with the average being 3.1 disorders 
per detainee, which was considerably higher than 
that in the mental health group. Of the offender 
group, 18.5% reported experiencing thoughts of 
suicide, and the same percentage reported that 
they had attempted to take their lives on at least 
one occasion. Over one-third (38%) met diagnostic 
criteria for internalising (emotional) disorders 
such as anxiety and depression, and 68% for 
externalising (disruptive) disorders such as conduct 
and attention defi cit disorders. 
Sixty-seven per cent of the offender group met the 
criteria for at least one substance-related disorder. 
Approximately equal numbers reported using 
cocaine (13/30), alcohol (14/30) and cannabis 
(14/30). Based on participants’ reports of substance 
use in the 12 months prior to interview, researchers 
assigned them to one of three categories: 
dependency disorder (those addicted to one or 
more substance, n=14); use disorder (regular users 
of one or more drugs but who did not have a 
diagnosis of addiction, n=5); sporadic users (those 
who had used drugs in the past 12 months but 
not in suffi cient quantities to warrant a diagnosis 
of dependency or use disorder, n=5) (Figure 1). 
One member of the offender group reported not 
having taken any drugs or alcohol in the previous 
12 months. 
Detainees with substance dependency disorders 
reported that they fi rst began to use alcohol and 
cannabis at an average age of just nine years, 
and cocaine at 13 years. The majority did not 
receive treatment for psychiatric or substance use 
problems. Despite incarceration, these boys had 
continued access to alcohol and drugs, possibly 
through home leave, during family visits or during 
court appearances. According to the authors, this 
continued access to drugs and alcohol served to 
sustain their dependency and use diffi culties. 
A total of 335 crimes were committed by the 
30 young detainees. These offences included 
acquisitive crimes, property crimes, driving 
offences, violent interpersonal offences, and failure 
to comply with a Garda/court order. Figure 2 shows 
the number of charges within each crime category.
The largest crime category was acquisitive crime, 
with 123 charges being held by 25 of the 30 young 
detainees. Although the majority of this group had 
substance-related disorders, none was detained 
Figure 1 Substances used by young offenders in the year prior to interview
Source: Hayes and O’Reilly (2007)
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Figure 2 Number of criminal charges against respondents, by crime category
Source: Hayes and O’Reilly (2007:23)
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on an alcohol-related charge, and only one held 
a drug-related charge (possession of a controlled 
substance). The results also indicate high rates of 
recidivism, with over three-quarters (76.7%) of the 
sample having been detained on at least one other 
occasion. 
The authors conclude that the level of criminality 
among youths in detention schools is very serious, 
with about one in three detainees charged with at 
least one offence relating to interpersonal violent 
crime. They state that the emotional intelligence 
defi cits of the detainees may make it diffi cult for 
them to fully understand how their offending 
behaviour impacts on others, and that ‘a reduced 
capacity to regulate emotions could maintain 
offending patterns of behaviour in detainees’ (p. 
55).
The authors highlight the importance of addressing 
mental health and substance use among children 
in detention schools. They believe that, in addition 
to reducing the debilitating effect of mental 
health problems on a child’s functioning and 
development, treatment will lead to a signifi cant 
reduction in offending behaviour and criminality, 
with signifi cant cost benefi ts for society, the legal 
system and the Irish State.
(Angela Morgan, Jean Long and Johnny Connolly)
1. Hayes JM and O’Reilly G (2007) Emotional 
intelligence, mental health and juvenile 
delinquency. Cork: Juvenile Mental Health 
Matters.
Detention schools (continued)
Public attitudes to mental health
In January 2007, the National Offi ce for Suicide 
Prevention of the Health Service Executive 
commissioned research on public attitudes 
to mental health.1 One thousand adults were 
interviewed in their own homes in January and 
February 2007. The overall objective of this research 
was to obtain a comprehensive view of attitudes 
to mental health, which will be used to inform a 
mental health awareness and attitudes campaign 
as set out in Action 10.1 of Reach Out, the National 
Strategy for Action on Suicide Prevention. 
The survey found that more than eight in ten Irish 
adults (86%) considered their overall quality of life 
to be ‘good’ or ‘very good’. However, this fell to 
64% among those who had experienced mental 
health problems themselves. There was also some 
discontent with certain aspects of our society today, 
with 62% believing that ‘these days people don’t 
really know who they can count on’, and 44% 
agreeing that ‘people were better off in the old 
days when everyone knew how they were expected 
to act’. These feelings were more acutely felt by the 
over-35s. 
Only 11% reported having experienced mental 
health problems themselves; the authors felt that this 
fi gure could be an understatement, in view of the 
sensitivity of the issue. Most experts agree that, in 
reality, one in four people experience a mental health 
problem at some stage in their lives. Twenty-three 
per cent reported having cared for or being related 
to someone who had mental health problems. Those 
working in the home and those who were separated, 
divorced or widowed tended to have more direct 
experience of mental health problems. Fifty-nine per 
cent claimed to have no direct or indirect experience 
of mental health problems.
While a substantial proportion of people (85%) 
agreed that ‘anyone can experience mental health 
problems’, this report reveals that stigma still exists 
in relation to mental health. Sixty-two per cent 
of respondents would not want people knowing 
about it if they themselves were experiencing 
mental health problems; 52% agreed that people 
with mental health problems should not be allowed 
to do important jobs, as doctors or nurses, for 
instance; and just 48% believed that the majority of 
people with mental health problems do recover.
Opinion was quite polarised on some issues related 
to mental health and there appeared to be fear 
among the general public surrounding mental 
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Public attitudes (continued)
health problems. Thirty-nine per cent felt that the public 
should be better protected from people with mental health 
problems; 36% felt that people with mental health problems 
were often dangerous; and 33% admitted that they would 
fi nd it hard to talk to someone with mental health problems. 
However, 65% agreed that people with mental health 
problems were not to blame for their problems and 43% 
feared that they themselves might experience mental health 
problems in the future. Overall, there appeared to be an 
inherent acceptance that we are all potentially vulnerable to 
mental health problems.
There was an under-estimation of the prevalence of 
mental health problems in Ireland. Two-thirds estimated a 
prevalence of one in ten or less, while only 5% estimated a 
prevalence of one in four. Suicide (25%), alcoholism (19%) 
and depression (19%) were identifi ed as the top three most 
important mental health problems that needed to be tackled 
in Ireland. Drug dependence was cited by 13% as the single 
most important health problem in Ireland. Men were more 
likely than women to identify alcoholism (22% vs. 19%) or 
drug dependence (17% vs. 13%) as the most important 
mental health problem. 
The majority of Irish adults (74%) would consult their GP if 
they thought they had a mental health problem, and one 
in fi ve would also turn to close friends or family for support. 
Specialist medical services, including those of counsellors, 
therapists, psychiatrists and psychologists, were considered 
less obvious sources of support. Those who had experienced 
mental health problems were most likely to seek support 
from their GP, counsellor/therapist and close friends. 
This report identifi ed a number of key areas where targeted 
education and awareness are required. These include 
education of the public on the true prevalence of mental 
health problems, focusing on eroding the stigma in relation 
to mental health, and increasing personal awareness of 
mental health.
(Deirdre Mongan)
1. National Offi ce for Suicide Prevention (2007) Mental 
health awareness and attitudes survey. Dublin: Health 
Service Executive. 
On 12 December 2006, the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) requested each 
national focal point to complete a questionnaire recording 
the use of 1-benzylpiperazine (BZP) in their country. The 
questionnaire allows formal exchange of information 
between member countries and the EMCDDA. 
In Ireland the questionnaire was completed by the Alcohol 
and Drug Research Unit (ADRU) of the Health Research 
Board, and the Forensic Science Laboratory. The ADRU 
collated what was known about BZP in Ireland through 
literature, website and newspaper searches. The Forensic 
Science Laboratory reported the number of BZP seizures and 
described their contents. 
BZP is not classifi ed as a controlled drug and does not 
come under Ireland’s Misuse of Drugs Act 1977. According 
to media reports, BZP is sold on the street outside major 
dance and music venues as well as in ‘head/smart shops’, 
often marketed as a ‘legal alternative to ecstasy’ and other 
stimulants, and purportedly sold only to people aged 18 or 
over. Recent newspaper reports indicate that the price of a 
BZP tablet in these shops ranges from €6.00 to €8.50. The 
Forensic Science Laboratory analysed samples from four BZP 
seizures in 2006. 
A Europol–EMCDDA joint report1 cited a New Zealand 
‘National household survey of legal party pill use’ (2006) 
involving 2,010 respondents aged 13–45. This survey found 
that the psychological problems most often experienced 
following legal party pill use were ‘trouble sleeping’ (50.4%), 
‘loss of energy’ (18.4%), ‘strange thoughts’ (15.6%), ‘mood 
swings’ (14.8%), ‘confusion’ (12.1%) and ‘irritability’ 
(11.4%). The physical problems most often experienced 
were ‘poor appetite’ (41.1%), ‘hot/cold fl ushes’ (30.6%), 
‘heavy sweating’ (23.4%), ‘stomach pains/nausea’ (22.2%), 
‘headaches’ (21.9%) and ‘tremors and shakes’ (18.4%). 
A recent New Zealand Medical Journal article described 80 
BZP-related emergency department admissions occurring at 
Christchurch Hospital over a six-month period in 2005. The 
authors concluded that BZP can cause unpredictable and 
serious poisoning in some cases, and advised that people 
who have illnesses associated with seizures or heart disease 
should avoid using it. BZP was found in the body fl uids 
of a small number of people who died in Malta, Sweden, 
Switzerland and the UK. Other stimulants and drugs were 
also present in these body fl uids, making it diffi cult to 
determine the exact role of BZP in each fatality. 
The information collated by Europol and the EMCDDA 
indicated that the health and social risks caused by the 
use and manufacture of, and traffi c in, BZP, as well as the 
involvement of organised crime and possible consequences 
of control measures, could be thoroughly assessed by means 
of the risk assessment procedure outlined in Article 6 of 
Council Decision 2005/387/JHA. 
On 30 May 2007, the Scientifi c Committee of the EMCDDA 
completed a risk assessment for BZP. ‘The overall conclusion 
of the Committee was that due to its stimulant properties, 
risk to health and the lack of medical benefi ts, there is a 
need to control BZP. However, the Committee felt that the 
control measures should be appropriate to the relatively low 
risks of the substance.’2
On foot of a proposal presented by the Commission to 
the European Council on 17 July 2007, the Council issued 
its decision that ‘Member States shall take the necessary 
measures, in accordance with their national law, to submit 
[BZP] to control measures, proportionate to the risks of the 
substance, and criminal penalties, as provided for under their 
legislation …’ (COM(2007) 430 fi nal).
(Jean Long)
1. Europol–EMCDDA Joint report on a new psychoactive 
substance: 1-benzylpiperazine (BZP) (2007) http://www.
emcdda.europa.eu/?nnodeID=16775 Accessed 21 June 
2007.
2. CORDROGUE 35 10458/07 - Risk assessment report of a 
new psychoactive substance: 1-benzylpiperazine (BZP). In 
accordance with Article 6 of Council Decision 2005/387/
JHA on information exchange, risk assessment and 
control of new psychoactive substances.
BZP – information exchange, risk 
assessment and control measures
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In July 2007 the European Foundation of Drug 
Helplines (FESAT) published the results from its 
thirteenth monitoring project.1 Since the beginning 
of 2001 FESAT has been collecting information 
every six months on the types of person contacting 
helplines, the content of these calls and how this 
has changed compared to the previous six months. 
According to the author, the main objective of 
this monitoring is to identify the emergence of 
new drugs and new drug trends; the data cannot 
quantify the size of any such changes. 
Of the 34 relevant FESAT helplines, 18 helplines 
in 13 European countries, including Ireland, 
participated in the project. This article will describe 
some of the main changes that were reported by 
the helplines in Europe during the second half of 
2006 when compared to the fi rst half of 2006. The 
article also presents some unpublished information 
from the Drugs/HIV Helpline in Ireland. 
The smallest of the 18 participating helplines in 
Europe answered an average of one call every 
second day, and the largest, 108 calls per day. 
Seven helplines answered 10 calls or fewer per 
day; eight helplines answered 11 to 30 calls; two 
helplines answered 31 to 60 calls and one helpline 
answered 61 or more calls. Half of the helplines 
answer 16 or more calls per day. The Drugs/HIV 
Helpline in Ireland answered an average of 15 
calls per working day, though this fi gure included 
calls about sexual health. There were 1,875 
calls between July and December 2006, which 
represents a 12% decrease when compared to 
the preceding six-month period. This decrease is 
consistent with other years, as the helpline receives 
more calls in the fi rst six months of the year than in 
the second six months; this might be explained by 
summer and Christmas holidays (Aileen Dooley, of 
the Drugs/HIV Helpline personal communication, 
2007).
The FESAT report notes a decline in the numbers 
of helplines reporting calls about cocaine 
and cannabis across Europe and an increase 
in the number of calls about GHB (gamma-
hydroxybutyrate) (six helplines), amphetamines 
(fi ve helplines) and benzodiazepines (fi ve helplines). 
The number of helplines answering calls about 
alcohol (six helplines) remained stable. There were 
decreases in the numbers of calls about injecting 
heroin, magic mushrooms and ecstasy. 
In Ireland, there was a large decrease in the number 
of calls to the Drugs/HIV Helpline about cocaine, 
from 226 in the fi rst half of 2006 to 166 in the 
second half of 2006. There was some decrease in 
the number of calls about alcohol, from 238 in 
the fi rst half of 2006 to 201 in the second half of 
2006. There was a large decrease in the number of 
calls about cannabis, amphetamines and injecting 
heroin in the second half of 2006 when compared 
to the fi rst half of 2006. There was some increase in 
the number of calls about poppers (Aileen Dooley, 
personal communication, 2007).
During the second half of 2006, two helplines 
in Europe received calls about drugs that had 
not been reported to them before. The Drugs/
HIV Helpline in Ireland answered calls about fi ve 
substances for the fi rst time. Chief among these 
was LSA (d-lysergic acid amide), which occurs 
in the seeds of the morning glory plant and has 
hallucinogenic effects. Bearing out reports from 
the Forensic Science Laboratory in Ireland, the Irish 
helpline answered calls about benzylpiperazine 
(also known as BZP and marketed as ‘Jacks’), which 
is taken orally and has effects similar to those of 
ecstasy. Also new to the Irish helpline in 2006 were 
calls about GHB, which is normally available as a 
liquid. Other substances mentioned for the fi rst 
time were Salvia and Subutex. Salvia divinorum 
has hallucinogenic effects and can be smoked or 
chewed. Subutex (buprenorphine) is an opiate 
used in the management of opiate addiction. The 
Norwegian helpline reported fi rst-time calls about 
the opioid analgesic tramadol (trade name Tramal), 
which is normally taken orally as a capsule, but 
which can be injected.
(Jean Long)
1. Hibell B (2007) FESAT Monitoring Project  – 
Changes during the second half of 2006. Brussels: 
FESAT (The European Foundation of Drug 
Helplines). 
More information about FESAT can be found at 
www.fesat.org.
Identifying new drugs and new 
drug trends with the help of drug 
helplines
The Drugs/HIV Helpline in Ireland is a 
confi dential, freephone, active listening 
service offering non-directive support, 
information, guidance and referral 
to anyone with a question related to 
substance use or HIV and sexual health. Set 
up in July 1997, the service is funded and 
managed by the Health Service Executive.
The freephone number is 1800 459 459. 
The Helpline manager is Aileen Dooley.
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On 21 July 2007 it was exactly 10 years since 
the Irish Drugs/HIV Helpline fi rst opened its lines 
to callers from across the country. On its 10th 
birthday, we refl ect on what has developed into 
a skilled, professional service that has a respected 
place among the substance use and sexual health 
services in Ireland. 
From the start, the ethos of the helpline was one of 
non-directive, non-judgmental support. Staff use 
active listening skills to help callers to explore their 
needs and, where appropriate, callers are given 
information and contact details of the services 
available to them. The focus is very much on the 
caller, whether a substance user, a parent, a son or 
daughter, a teacher, a student or a service provider. 
The helpline was established primarily as a source 
of drug-related information and support, with 
the additional aim of reducing HIV transmission 
and supporting those with a positive diagnosis, 
particularly if linked to drug use. Perhaps the 
greatest surprise of the helpline’s 10 years is how 
the HIV-related calls have developed. The service 
dealt with just 19 such calls in 1997 and 79 such 
calls in 1998, and now deals with over a 1,000 HIV 
calls each year. Also, 73% of callers who referred 
to a HIV concern in 2006 were concerned about 
sexual encounters as opposed to drug use. 
The drug-related calls have shown interesting trends 
over the years. Cannabis has consistently been 
the drug most often referred to. In second place 
in terms of frequency were: heroin-related calls in 
2004, cocaine-related calls in 2005, and alcohol-
related calls in 2006. Helpline records can indicate 
trends in substance use and are a valuable source of 
information about drug use among individuals who 
are not engaged with treatment services. 
The helpline has developed a database of over 
300 relevant services nationwide. This is updated 
regularly and is used in conjunction with a 
computerised call-logging system to ensure that the 
best quality information is given to callers and that 
detailed anonymous data on calls can be collated 
and statistically analysed. This database is a useful 
resource not only for people seeking support but 
also for professionals working in the fi eld who wish 
to ensure that the referral options that they give to 
clients are up to date. 
In 10 years the helpline has dealt with over 45,000 
calls. We hope to build on its strengths and focus 
on improving the quality of the service provided 
to the public. We hope that in the coming years 
the helpline will offi cially become a national 
service, and that staff vacancies will be fi lled and 
opening hours extended. We hope to publish 
some research related to call data and to make our 
services database an online resource. The helpline is 
currently open from Monday to Friday from 10 am. 
If you have any questions about this service, please 
give us a call.
(Aileen Dooley)
The Survey of Lifestyle, Attitudes and Nutrition 
(SLAN) is a national, cross-sectional, postal survey 
of adults in Ireland. It was fi rst conducted in 19981 
by the National University of Ireland, Galway, with 
a second survey carried out in 2002.2 The surveys 
obtained 6,539 valid responses in 1998 and 5,991 in 
2002. A section of each survey collected information 
on drug use. Participants were asked about their 
experiences of using the following illicit drugs:
marijuana or cannabis ■
non-prescription tranquillisers or sedatives  ■
amphetamine ■
LSD  ■
cocaine ■
heroin  ■
ecstasy ■
drugs by injection with a needle, e.g. heroin,  ■
cocaine or amphetamines
solvents ■
magic mushrooms ■
For all the drugs listed except cannabis, the study 
collected data on use within the 12 months prior to 
the survey. Data on the frequency of cannabis use 
were collected for three time periods: within the 
last 30 days, within the last 12 months and within 
the respondent’s lifetime. For the most part, the 
fi gures in this article refer to drug use within the 
past 12 months, referred to as ‘current’ drug use. 
In 1998 1,143 people (17.5%) reported taking 
illegal drugs at some point in their lives; this fi gure 
increased to 1,173 (19.6%) in 2002. In both 
years the rate of current drug use was 7.6% of 
the population surveyed, which equated to 494 
respondents in 1998 and 453 in 2002. In 1998, 
27.3% of the drug-taking population had taken 
one of the drugs listed above in the previous 12 
months; this decreased to 25.4% in 2002. 
Cannabis was the most commonly used illegal 
drug, with lifetime use rates of 16.3% in 1998 and 
18.6% in 2002, and current use rates of 6.2% in 
1998 and 6.3% in 2002. The vast majority of those 
who reported taking only one drug used cannabis. 
In 1998, 89.6% of illicit drug users had taken 
cannabis within the past year, decreasing to 88.1% 
in 2002. Non-prescription tranquillisers or sedatives 
Happy 10th birthday to the Drugs/
HIV Helpline
SLAN survey data on illicit drug use
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were the second most commonly taken drugs. Nineteen per 
cent reported using these drugs in 1998, decreasing to 13% 
in 2002. 
The study also examined concurrent polydrug use. This is 
the use of different drugs on separate occasions within a 12-
month period. Concurrent polydrug use was lower in 2002 
than in 1998. Over 6% of current drug users reported using 
two of the above drugs in 1998 and 5.4% reported such use 
in 2002. In 1998, 9.4% used three or more drugs, while in 
2002 the corresponding percentage was 7.8%. Cannabis 
was the drug most widely availed of by polydrug users; 
96.7% had taken cannabis at some point in their lives and 
82.4% were taking it concurrently with other drugs. Over 
one in six current polydrug users had taken cannabis before 
progressing on to other drugs, and over three-quarters of 
those engaging in polydrug use had taken cannabis within 
the last 12 months.
After cannabis, ecstasy was the illicit drug used most 
frequently in conjunction with other drugs. Eighty per cent 
of those who took drugs by injection also reported ecstasy 
use. Similarly, 71% of LSD users, 67.1% of cocaine users, 
64.2% of amphetamine users and 21.4% of cannabis users 
also took ecstasy. There was a close link between heroin and 
cocaine use, with four out of fi ve heroin users reporting that 
they also took cocaine.
Heavy drinkers and binge drinkers were more likely than 
social drinkers and non-drinkers to report illicit drug use. 
The average alcohol intake of those who reported using 
drugs was 6.5 units per drinking occasion, compared to 4.5 
units in the non-drug-taking populace. Similarly, regular 
and occasional cigarette smokers reported a higher level of 
illicit drug use than non-smokers. Over one-third of drug 
users smoked regularly and 8.2% smoked occasionally, while 
among non drug-users only 20.1% smoked regularly and 
2.9% smoked occasionally. 
Gender was an important determinant of level of drug use, 
with 9.2% of men surveyed disclosing that they had taken 
drugs in the last 12 months, as opposed to 6.4% of women. 
Also, 4% of men surveyed were current polydrug users, 
in comparison to 2% of women. Of the 940 respondents 
who were currently using drugs, 21.1% of men and 14.5% 
of women were polydrug users. Men aged between 20 
and 24 years were the most frequent users of illicit drugs, 
comprising over one-fi fth of all current drug users and 
just under one-third of current polydrug users. One in fi ve 
women aged between 20 and 24 years reported that they 
were current drug users, of whom almost one-fi fth were 
polydrug users. 
It must be noted that there are limits to the extent to which 
the SLAN data typify the level of illicit drug use in Ireland. The 
SLAN survey is not designed to collect information specifi cally 
about drug use and the amount of space it can devote to 
such questions is limited. Nevertheless, the SLAN data do offer 
useful insights about illicit drug trends in Ireland. A third SLAN 
survey is due for publication in late 2007.
(Aileen Connor)
1. Friel S, Nic Gabhainn S and Kelleher C (1999) The 
national health & lifestyle surveys: survey of lifestyle, 
attitudes and nutrition (SLAN) & the Irish health behaviour 
in school-aged children survey (HBSC). Galway: National 
University of Ireland. 
2. Kelleher C, Nic Gabhainn S, Friel S, Corrigan H, Nolan 
G, Sixsmith J et al. (2003) The national health & lifestyle 
surveys: survey of lifestyle, attitudes and nutrition (SLAN) 
& the Irish health behaviour in school-aged children survey 
(HBSC). Galway: National University of Ireland. 
SLAN survey data on illicit drug use (continued)
The National Documentation Centre (NDC) continues to 
develop its library of electronic and print resources in the 
area of drug use and problem alcohol use. We have recently 
compiled a list of postgraduate theses relating to drugs 
and alcohol completed in third-level institutions in Ireland 
(including Northern Ireland). We have added this list to a 
new ‘ Thesis’ page on our website (www.hrb.ie/ndc). 
The Thesis page is searchable by keyword, and results can 
be sorted by author or by institution. To date, we have a 
record of 208 theses from 10 third-level institutions; 165 
of these contain abstracts. All aspects of problem drug 
and alcohol use, including education, prevention, social 
policy and treatment, are represented. The record also 
includes work in related areas of research with a signifi cant 
drug- or alcohol-related component, such as homelessness, 
prostitution, crime, infectious diseases and social exclusion. 
Information for the thesis listed was sourced from a wide 
range of disciplines, including addiction studies, geography 
and, even, architecture.
The Thesis page was originally targeted at students. 
However, in view of the broad range of topics represented, 
we believe that this new resource will be of value to a 
wider audience. This is a great opportunity to disseminate 
information on postgraduate research as masters and 
doctoral theses are primary literature and are valuable 
contributions to the world of research.
The NDC does not hold copies of theses in its library.  Most 
of those listed can be accessed through the library of the 
relevant institution shown in the record; the location and 
shelf number are given where possible. 
To include a record of your thesis on our database:
If your thesis or dissertation is NOT currently listed on our 
Thesis page, we invite you to send the following information 
to ndc@hrb.ie:
your name ■
the title of your thesis ■
the year of completion ■
the associated third-level institution ■
the degree awarded (e.g. MA, MSc, PhD) ■
an abstract of your work (250 words). ■
If you fi nd an error in your listing, or would like to add 
information (such as an abstract), please send an e-mail to 
ndc@hrb.ie. Please indicate that you are correcting a listing 
already in the database. 
(Mairea Nelson)
New NDC information resource: Thesis 
page
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On 18 April 2007 the European Commission (Anti-Drugs 
Policy Coordination Unit in the DG for Justice, Freedom 
and Security) published its report on the results of the open 
consultation on the Green Paper on the role of civil society 
in drugs policy in the EU.1 The Commission has invited civil 
society organisations (CSOs) to apply for membership of a 
Forum that will serve as a platform for informal exchanges 
of views and information between the Commission and 
CSOs on drugs policy. The fi rst meeting of the Forum will 
be held before the end of 2007. The future of this initiative 
is conditional on the adoption by the EU of the ‘Drugs 
Prevention and Information Programme 2007–2013’. www.
ec.europa.eu 
In April 2007 a report Addressing issues of social exclusion 
in Moyross and other disadvantaged areas of Limerick 
City was delivered to the Cabinet Committee on Social 
Inclusion. In respect of drugs and other problems, author 
John Fitzgerald stated that co-ordination of services was not 
enough and there needed to be ‘special dedicated teams’ 
to provide ‘full service integration’. He also recommended 
that ‘a local focus’ for drug-related interventions should 
be immediately established for Limerick City and it should 
work closely with the development agencies to identify 
appropriate interventions. www.limerickcity.ie 
On 9 May 2007 a BA in Applied Addiction Studies, the 
fi rst Irish undergraduate degree in addiction studies, was 
launched. It was developed by the Addiction Training Institute 
in partnership with Athlone Institute of Technology. www.
addiction.ie 
Between 13 and 17 May 2007 the International Harm 
Reduction Association (IHRA) held its 18th annual 
conference in Poland. The theme of the conference was 
‘Harm Reduction: Coming of Age’. It included around 90 
sessions covering illicit drugs, alcohol, tobacco, sex work, 
HIV/AIDS, young people, and prisons. www.ihra.net 
In May 2007 a Hepatitis Group was established by the 
Health Service Executive (HSE) to make recommendations 
on an action plan for hepatitis C in Ireland. Comprising 
20 people, the Group will report on priority actions in 
relation to hepatitis C. It is looking at hepatitis C from the 
perspective of surveillance, treatment and prevention. The 
Group may be contacted via joebarry@tcd.ie
On 12–13 June 2007 the fi rst Annual progress review on 
the implementation of the EU Drugs Action Plan 2005–
2008 (doc. 17101/06 CORDROGUE 118) was adopted at a 
meeting of the Justice and Home Affairs Council of Europe. 
www.europa.eu 
On 18 June 2007 the Organised Crime Task Force (OCTF) 
in Northern Ireland published its annual report for 2006. 
It reported that over £22 million worth of drugs had been 
seized. It anticipated that illicit drugs will continue to pose a 
serious threat in 2007/8. www.octf.gov.uk
On 26 June 2007, International Day against Drug Abuse 
and Illicit Traffi cking, the UN Offi ce for Drugs and Crime 
(UNODC) launched an anti-drugs campaign with the slogan 
‘Do drugs control your life? Your life. Your community. No 
place for drugs.’ The slogan will be used for three years, 
focusing on drug abuse in 2007, drug cultivation and 
production in 2008, and illicit drug traffi cking in 2009. 
The aim is to inspire and mobilise people to support drug 
control. www.unodc.org 
In June 2007 Removing the boundaries: a profi le of 
drug prevalence in North County Dublin was published 
by North Dublin City and County Regional Drugs Task 
Force. The study fi nds that problem drug use in North 
County Dublin is more hidden than in Dublin Inner City. It 
suggests this may be because of the rural nature of much 
of North County Dublin, with small close-knit communities, 
where individuals might feel more stigmatised than in 
the city if they were to declare their problem. In addition, 
opportunities for local treatment are lacking, other than 
in Swords/Donabate; service users from other areas must 
travel daily to the city to obtain treatment and/or to fi ll 
prescriptions. www.ndublinrdtf.ie 
On 29 June 2007 the European Centre for Disease 
Prevention and Control (ECDC) and the EMCDDA signed 
a co-operation agreement to tackle drug-related infectious 
diseases and to contribute to the broader EU effort to 
prevent and control communicable diseases. Areas of mutual 
interest will be identifi ed by the agencies and implemented 
through projects relating specifi cally to epidemiology and 
disease prevention and control. www.emcdda.eu 
On 1–3 July 2007 the fi rst world conference on medication-
assisted treatment of opiate addiction, together with 
the inaugural meeting of the World Federation for the 
Associations for the Treatment of Opioid Dependence 
(WFATOD), was held in Ljubljana, Slovenia. www.seea.net 
On 12 July 2007 Barnardos’ Annual review 2006: no child 
gets left behind was launched. It contains the following 
observation, ‘Oftentimes children are referred to Barnardos 
because they are missing school. When we meet with the 
family it becomes clear that school attendance is an outward 
symptom of what’s happening at home. There may be issues 
such as alcoholism, drug abuse, depression, separation and 
loss. … When you work with the whole family, you can make 
changes in the home and have a major impact on a child’s 
life.’ www.barnardos.ie 
In July 2007 a consultation paper Drugs: Our Community, 
Your Say was launched in the UK. It marks the preliminary 
stage in developing the next national drugs strategy for the 
UK. The current strategy expires in 2008. www.homeoffi ce.
gov.uk 
(Compiled by Brigid Pike)
1. For an overview of the Green Paper and of the broader 
debate on the role of civil society in policy development 
at EU and UN level, see Pike B (2006) Civil society to 
have a role in EU drugs policy. Drugnet Ireland, Issue 19: 
19–20. 
In brief
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Raising awareness of HPV
Cited from article by Alessandro Pirona and Dagmar 
Hedrich, Drugnet Europe No. 59, July–September 
2007, p.3 
The recent authorisation by the European 
Commission of a prophylactic vaccine against 
the Human Papilloma Virus (HPV) could greatly 
improve the prevention of HPV infections in Europe 
and help reduce the incidence of cervical cancer.
HPV is highly transmissible and is linked to virtually 
all cervical cancer cases. According to the World 
Health Organisation (WHO), it is the second biggest 
cause of female cancer mortality worldwide, 
claiming around 250,000 lives annually. Every year, 
some 15,000 women die from this preventable 
disease in Europe, with the newer EU Member 
States reporting twice as many cervical cancer cases 
as the old EU-15. …
Young female drug users, especially those involved 
in sex work, are at a high risk of contracting 
sexually transmitted infections (STIs), including 
HPV, due to high levels of risky sexual behaviour. 
Studies conducted in Spain and Denmark showed 
that, in all age groups, HPV prevalence was highest 
among female sex workers (over 65% in the ‘under-
20’ year group), followed by women attending STI 
clinics and in prison. …
Outreach health services and STI or HIV clinics 
linked to drug treatment services can contribute to 
raising awareness on HPV and to increasing vaccine 
coverage by disseminating information to young 
female drug users. However, targeted cervical 
screening and safe-sex practices remain crucial 
components in preventing cervical cancer.
Local authorities, a ‘logical partner’ in tackling 
drugs
Cited from paper released by Wolfgang Götz, 
EMCDDA Director on 26 June 2007, Drugnet Europe 
No. 59, July–September 2007, p.4. 
Local authorities are a logical partner in dealing 
with drug-related problems. They are best placed 
to fi ne-tune and adapt drug policies to the needs 
and resources of their community. They are also 
at the frontline in the fi ght against drug-related 
crime and in dealing with the social repercussions 
of drug use.
One of the main tests for local decision-makers 
is fi nding the right balance between protecting 
the wider community against drug-related 
crime, on the one hand, and, on the other hand, 
helping drug users through social and healthcare 
interventions to reduce their risk-taking and guide 
them into treatment.
Treating drug users is very often the domain of 
local authorities, as services are frequently managed 
and fi nanced at local level. I believe that one of the 
main challenges for local authorities in the coming 
years in tackling drugs will be precisely in this area. 
One reason is that, although treatment centres are 
generally more numerous and better equipped 
today than they were a decade ago, they are still 
very much geared towards problems relating to 
heroin use (e.g. there are now over half a million 
people in Europe in drug substitution treatment). 
But, as more and more individuals seek treatment 
for problems linked to synthetic drugs, cannabis, 
cocaine or polydrug use, services will need to adapt 
to more, and very varied, problems.
Among the new developments we have witnessed 
in the last fi ve years in the prevention of drug use in 
Europe is ‘selective prevention’, aimed at high-risk 
groups, families and communities who are often 
by-passed by prevention work in more traditional 
settings.
Our 2006 Annual Report noted a greater 
involvement here of municipalities, as selective 
prevention calls for cooperation between youth, 
education, health, social and law enforcement 
services which is typically local.
Drug-related public expenditure
Cited from an article by Xavier Poos, Drugnet Europe 
No. 59, July–September 2007, p.6. 
‘Producing estimates of public expenditure on 
drugs’ is a key objective of the current EU drugs 
action plan (2005–2008). In this context, the 
EMCDDA will support the European Commission 
and EU Member States in developing a common 
methodology to estimate direct and indirect drug-
related expenditure in the EU, candidate countries 
and Norway.
Current research at the EMCDDA is aimed at 
identifying, developing and testing methods at EU 
level for quantifying public expenditure in this fi eld. 
In close collaboration with the Reitox network and 
international experts, the agency is also working 
on a ‘Selected issue’ on public expenditure to be 
released alongside its 2008 Annual Report.
From Drugnet Europe
Drugnet Europe is the quarterly 
newsletter of the European Monitoring 
Centre for Drugs and Drug Addiction 
(EMCDDA). Drugs in focus is a series of 
policy briefi ngs published by the EMCDDA. 
Both publications are available at www.
emcdda.europa.eu.
If you would like a hard copy of the current 
or future issues of either publication, please 
contact: Alcohol and Drug Research Unit, 
Health Research Board, Knockmaun House, 
42–47 Lower Mount Street, Dublin 2. 
Tel: 01 2345 127; Email: adru@hrb.ie.
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No. 16: Drugs and crime – a complex relationship
To advance the overall EU drugs strategy’s aim of ensuring 
a high level of security for the general public, the EU drugs 
action plan 2005–2008 includes an explicit action to develop 
a common defi nition of drug-related crime. This policy 
briefi ng, No 16, explores the different types of offences that 
might be encompassed under a general heading of drug-
related crime, and proposes a defi nition encompassing four 
categories:
Psychopharmacological crimes: crimes committed under 1. 
the infl uence of a psychoactive substance, as a result of 
its acute or chronic use;
Economic-compulsive crimes: crimes committed in order 2. 
to obtain money (or drugs) to support drug use;
Systemic crimes: crimes committed within the functioning 3. 
of illicit drug markets, as part of the business of drug supply, 
distribution and use; and
Drug law offences: crimes committed in violation of drug 4. 
(and other related) legislation.
The briefi ng concludes with a series of considerations for 
policy-makers:
A range of factors and conditions lead offending and  ■
drug-using populations to follow a variety of pathways, 
each of which may make a specifi c and distinct 
connection between drugs and crime. Responses to 
drug-related crime therefore need to be complex, 
differentiated and targeted.
Understanding the links between drugs and crime is  ■
not merely of theoretical interest but also has profound 
implications for public policy, as knowledge of these links 
determines how society responds to drug-related crime. 
Thus, it is necessary to promote research in Europe on 
the drug–crime link and its various connections in order 
to determine how to reduce drug-related crime.
Although defi ning drug-related crime is a reductive  ■
exercise that cannot account for the whole complexity 
of the drug–crime nexus, a clear defi nition of the term 
‘drug-related crime’ is required as a prerequisite for 
evaluation.
There is a need in Europe to develop sound  ■
methodologies, based on multi-source models, for 
assessing the extent and patterns of, and trends in, drug-
related crime. 
National estimates of the extent and patterns of drug- ■
related crime are essential if studies of the social costs of 
drugs are to become meaningful, as such studies often 
face diffi culties in taking into account crimes other than 
drug law offences.
Methodologies to estimate drug-related crime will help  ■
to improve evaluation of the effect of interventions and 
measures aimed at reducing drug-related crime, both 
in the fi eld of drug demand reduction (treatment, harm 
reduction) and crime prevention/reduction (situational 
crime prevention, alternatives to imprisonment, social 
crime prevention).
Drugs in focus – policy brieﬁ ng
Books
Systematic reviews in the social 
sciences: a practical guide
Petticrew M and Roberts H
Blackwell Publishing 2006, 336 
pp.
ISBN 978 1 4051 2110 1
Aimed at social science 
researchers, this book is a step-
by-step guide to planning and 
conducting a systematic literature 
review. The authors do not deal 
exclusively with reviews of the 
effectiveness of interventions 
– the focus of most of the 
recent interest in systematic reviews (viz. the Campbell and 
Cochrane collaborations). They also look at the systematic 
review as a way of synthesising the evidence about a wide 
range of questions, moving beyond ‘What works?’ to ‘What’s 
important?’ Systematic reviews can provide evidence to 
address such questions as the prevalence of a problem, the 
correlation of two variables, the implementation, or costs, 
of a programme, or the meaning stakeholders ascribe to a 
programme or its context. They are also valuable as a method 
of mapping out areas of uncertainty and directing new 
research efforts.
This book outlines the rationale and methods of systematic 
review, drawing on examples from such diverse fi elds as 
psychology, criminology, education, transport, social welfare, 
public health, and housing and urban policy. It includes 
detailed sections on assessing the quality of both qualitative 
and quantitative research; searching for evidence in the 
social sciences; meta-analytic and other methods of evidence 
synthesis; publication bias; heterogeneity; and approaches 
to dissemination. The authors discuss some emerging 
issues – in particular the part played by different research 
designs in systematic reviews, including qualitative research; 
approaches to reviewing complex interventions; the means 
of dealing with variations between studies in terms of design 
and study quality; and ways of involving stakeholders in the 
process of planning and carrying out systematic reviews. 
Important information and useful tips are highlighted in text 
boxes throughout the book, and each chapter ends with 
summarised ‘Key learning points’.
Drugs, clubs and young people: 
sociological and public health 
perspectives
Sanders B (ed.)
Ashgate 2006, 200 pp.
ISBN 0 7546 4699 8
This edited collection of ten 
studies offers critical insights on 
drug use among young people 
by exploring and analysing 
behaviours common at raves 
and nightclubs from sociological 
and public health perspectives. 
Recent publications
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Material based on solid, empirical research is drawn 
from the US, the UK and Hong Kong to provide cross-
cultural comparisons, allowing for the demystifi cation of 
stereotypical presentations and the illumination of concerns 
surrounding young people who attend clubs and/or use club 
drugs. The contributions provide many theoretical insights 
related to illicit club drug use and supply, which aim, in part, 
to challenge current orthodoxies on the role of drug use 
within young people’s lives. 
The book is arranged in four sections. The opening two 
chapters are introductory, the fi rst an overview of raving, 
clubbing, club drugs and the responses they have generated, 
and the second an exploration of the origins of rave research 
in the UK and a discussion of the ramifi cations of personal 
experience in the course of researching the issues as a 
professional. The next three chapters comprise the second 
section and are concerned mainly with club drug use among 
young people in New York City. The next two chapters 
discuss the use of club drugs outside of club settings, 
focusing on ketamine and on ecstasy use among young, 
low-income women. The fi nal three chapters explore aspects 
and experiences of club drugs and ‘night-time economies’ 
in Hong Kong and London, and examine alcohol, club drugs 
(primarily ecstasy) and violence in clubs in the UK. The 
book has a 32-page bibliography and both a subject and an 
author index.
Drugs in society: European 
perspectives
Fountain J and Korf D (eds)
Radcliffe Publishing 2007, xvii, 
136 pp.
ISBN 978 184619 093 3 
This book’s editors and 
contributors are all members 
of the European Society for 
Social Drug Research (ESSD). 
ESSD was established in 
1990 with the principal aim 
of promoting social science 
approaches to drug research. 
This aim is refl ected in the focus of the ten papers included 
in the book, and in the Foreword by Paul Griffi ths of the 
European Monitoring Centre for Drugs and Drug Addiction, 
which warns: ‘It may be useful for many reasons to be able 
to describe general patterns of drug use in Europe but 
we forget at our peril the underlying reality of our subject 
matter.’ 
The diverse and wide-ranging papers presented here are 
unifi ed by a common perspective, where drug use is not 
simply reduced to questions of dependence or compulsion, 
and where the principal concern is not solely to audit 
consequences. Rather, the book is about drug use as a 
dynamic social behaviour where understanding meaning 
and motivations, and culture and context, are as important 
as understanding the actions of chemicals on the brain or 
body. This unique overview of the variation in the ways 
recreational and other drugs are used across Europe includes 
critical refl ections on current drug policy.
The papers describe studies by the various authors in 
the following areas: the perceptions of drugs and drug 
users in Portugal; Danish cannabis policy and practice; 
characteristics of the cannabis market in Belgium; ephedra 
for fun, performance and weight loss; khat and the Somali 
diaspora; life in exile and vulnerability factors for substance 
use; the stigma of drug use and the experience of prisoners 
in England and Wales; a system allowing the prescription of 
different substances for the maintenance of opioid addicts 
in Austria; methadone programmes, control strategies and 
responses; and description and analysis of some common 
logical fallacies in addiction research.
Journal articles
The following abstracts are cited from recently published 
articles relating to the drugs situation in Ireland.
Alcoholics Anonymous in Ireland: AA’s fi rst European 
experience
Butler S and Jordan T
Addiction 2007; 102(6): 879–886
The aim of this study was to trace the evolution of Alcoholics 
Anonymous in Ireland from its establishment there in 1946, 
focusing on the efforts of early members to publicize the 
fellowship and negotiate a role for themselves in relation to 
existing religious and healthcare institutions. The authors 
conducted archival research, drawing mainly on primary 
sources in AA archives in New York and Dublin. The authors 
found that anticipated tensions between this fellowship, 
which had its roots in Evangelical Protestantism, and the 
politically powerful Roman Catholic Church in Ireland were 
skilfully avoided; initial hostility from the medical profession 
quickly dissipated; and AA distanced itself from policy 
debate on the wider topic of alcoholism as disease. The 
authors conclude that the relatively smooth introduction 
of AA to Ireland, the fi rst European country in which it was 
established, may be attributable to the essentially pragmatic 
nature of the fellowship and the strategic abilities of its early 
members.
Characteristics of opiate users presenting for a new 
treatment episode: baseline data from the national drug 
treatment outcome study in Ireland (ROSIE)
Comiskey C and Cox G
Drugs: education, prevention and policy 2007; 14 (3): 
217–230
The Research Outcome Study in Ireland (ROSIE) is the 
fi rst large-scale, prospective, multi-site, drug treatment 
outcome study in Ireland, documenting progress at six-
month, one-year and three-year intervals. Using a structured 
questionnaire, the substance use, health, crime and social 
problems of 404 opiate users were assessed at treatment 
intake. While the majority of study participants were opiate 
users, polydrug use was the norm (76%, n = 308). Most 
participants had a history of injecting drug use (77%, n = 
308); however, only 42% (n = 170) reported injecting in the 
preceding 90 days. Participants reported a range of mental 
and physical health complaints and extensive contact with 
social care services. High crime rates were observed. Analysis 
revealed differences in the characteristics and substance 
use of participants across treatment modalities. The authors 
conclude that the range and severity of problems affecting 
individuals commencing treatment for their problem drug 
use highlights the complex needs of the cohort. These 
problems create substantial costs for providers of social care 
services in Ireland and can affect treatment outcomes.
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The human bite injury: a clinical audit and 
discussion regarding the management of this 
alcohol fuelled phenomenon
Henry FP, Purcell EM and Eadie PA
Emergency Medicine Journal 2007; 24(7): 455–458
Human bite injuries are both deceptive and 
challenging in their presentation and management. 
They remain a frequent presentation to our unit, 
most often following late night alcohol-fuelled 
aggression. The aim of this study was to audit the 
management of these wounds, with particular focus 
on infective complications and outcomes. A three-
year retrospective chart review was undertaken 
on all patients referred to the plastic surgery unit 
between 1 January 2003 and 31 December 2005. 
A total of 92 patients with 96 human bite wounds 
were identifi ed. The majority were male (92%). 
Alcohol consumption was documented in 86% 
of cases. The majority (70%) occurred over the 
weekend or on a public holiday. Facial injuries 
made up 70% of injuries, with the remainder being 
to the upper limb. The ear was the most common 
target of all facial injuries (65%). Infection was 
documented in 18 cases (20%), with bite injuries 
to the upper limb and those presenting late (more 
than 12 hours after the event) having a higher 
incidence of infection. The authors conclude that 
human bite wounds present a challenge to any 
emergency department, given the many issues 
involved in their management. Underestimation 
of the complexity and potential sequelae of these 
wounds will result in a suboptimal outcome for the 
patient.
Effectiveness of daily outpatient alcohol 
detoxifi cation by an Irish public psychiatric hospital 
– a pilot study
Agyapong V, Benbow J and Browne R
Irish Journal of Psychological Medicine 2007; 24(1): 
23–26
The aim of this study was to assess the effectiveness 
of daily outpatient detoxifi cation in an Irish public 
psychiatric hospital. The outpatient records of 
patients presenting to the Assessment Unit of St 
Brendan’s Hospital in one year (August 2004–July 
2005) with symptoms of alcohol dependence 
syndrome (ADS) and commencing daily outpatient 
detoxifi cation were examined retrospectively. 
The results were compiled and analysed using 
descriptive statistics.
Forty patients underwent outpatient alcohol 
detoxifi cation in one year and complete records 
were available for 32 patients (80%). Seven patients 
(22%) presented with co–morbid psychiatric 
conditions, including depression (four patients), 
anxiety disorder (two patients) and personality 
disorder (one patient). All seven patients were 
known to psychiatric sector services. Of the 32 
patients commencing detoxifi cation, 28 (87.5%) 
attended on the second day and 22 (69%) 
attended their third day’s appointment. Only 
17 patients (53%) completed the outpatient 
detoxifi cation. Thirteen patients (40.6%) received 
at least two outpatient detoxifi cations during the 
year, of whom seven (58%) received the second 
within two months of the fi rst. The records of 20 
patients (62.5%) showed that they had received 
advice regarding self-referral to counselling services.
The authors conclude that a high proportion of 
patients (47%) presenting with symptoms of ADS 
did not complete daily outpatient detoxifi cations. 
A high proportion of all patients (40.6%) also 
underwent multiple outpatient detoxifi cations 
during the year. It is possible that the separation 
between alcohol detoxifi cation and alcohol 
counselling services in Ireland contributed to these 
disappointing results. 
The homeless mentally ill – an audit from an inner 
city hospital
O,Neill A, Casey P and Minton R
Irish Journal of Psychological Medicine 2007; 24(2): 
62–66
The aim of this study was to determine the 
proportion of those that are homeless attending 
the Mater Hospital’s psychiatric service, including 
those presenting to accident and emergency who 
were homeless, and to compare the homeless 
group with the non-homeless so as to obtain a 
profi le of this group. All adults over 16, referred 
for psychiatric assessment, attending A&E were 
included, as were those attending outpatient 
clinics, liaison consultations and inpatients in the 
psychiatric unit, in the six-month period from 
January to June 2003. Excluded were those who 
were under 16, who refused to participate, who 
did not speak English, those with a diagnosis of 
personality disorder and organic brain damage. 
Questionnaires were completed by psychiatric 
registrars and a community psychiatric nurse, with 
an ICD-10 diagnosis recorded on each individual, 
in consultation with the treating consultant 
psychiatrist. 
A total of 628 patients were seen in MUH during 
the study period, and 13.8% were homeless. Of 
the homeless, 56.3% were seen as emergency 
referrals in the A&E, 23% were inpatients 
(including the psychiatric unit and consultations 
in medical/surgical wards) and 20.7% were seen 
in the outpatient department. Of all the A&E 
referrals to psychiatry, 34.8% were homeless. The 
homeless presented most commonly in suicidal 
crisis (26.6%) compared with 12.5% in the non-
homeless group. Substance-abuse disorders were 
the primary diagnosis in 42.3% of the homeless 
group, accounting for 14.2% in the housed sample. 
Outcome for both groups was similar, with slightly 
more homeless being referred for psychiatric 
admission (17.8%) compared to 12% in the 
non-homeless group. The authors conclude that 
mental illness and the need for psychiatric services 
remain a serious issue for a signifi cant segment 
of the homeless population. The homeless are 
over-represented in our accident and emergency 
department, with their psychological and medical 
needs not being met in primary care. An integrated 
multi-disciplinary treatment approach, including 
outreach work, that addresses their many needs, 
appears to hold the greatest promise of success in 
this population. 
(Compiled by Louise Farragher and Joan Moore)
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(Compiled by Louise Farragher – lfarragher@hrb.ie)
September
10–12 September 2007
European Association of Addiction Therapy, 3rd 
Annual Meeting
Venue: Palais Ferstel, Vienna, Austria
Organised by / Contact: EAAT, c/o RPA 
Communications Ltd, Unit 2B, Hampton Works, 
Sheen Lane, London, SW14 8AE
Tel: +44 (0)2084 871421
Email: info@eaat.org 
www.eaat.org
Information: EAAT 2007 provides a focus for 
understanding the scientifi c medical and social 
bases of addiction and a discussion forum to further 
develop relevant therapies throughout Europe. 
The conference also provides a central platform 
through which information can be disseminated 
across country and cultural boundaries. The EAAT 
will approach the problem of addiction from many 
different angles, and foster the evaluation and 
development of research strategies and treatment 
programmes. Through the annual conference 
and international collaborative ventures, the EAAT 
aims to improve our understanding of prevention 
and treatment of addictive behaviours, with much 
emphasis on psycho-pharmacological treatment.
20–22 September 2007
Addictions information in the Google era: dealing 
with challenges
Venue: Brussels, Belgium
Organised by / Contact: Marc Wauters, Elisad 
(European Association of Libraries and Information 
Services on Alcohol and other Drugs)
Email: marc.wauters@vad.be
www.elisad.eu 
Information: This will be the 19th Elisad annual 
meeting. Topics covered will include: 
Prevalence of alcohol and drug use in Belgium ■
Drug research in Flemish nightlife  ■
The Partywise prevention campaign ■
The Elisad portal for knowledge on substance  ■
abuse in Europe
The EU drug strategy  ■
Situation of AOD libraries in the USA  ■
The EMCDDA documentation centre  ■
Supporting evidence based practice  ■
Internet search tools in 2007 ■
Adding value beyond Google: controlled  ■
vocabulary and targeted information
21 September 2007
SMMGP 2nd National Conference. Bringing 
it Together: Effective primary care based drug 
treatment services – 07 and beyond
Venue: Burlington Hotel, Birmingham
Organised by / Contact: Substance Misuse 
Management in General Practice (SMMGP). 
Contact Heather Malcolm, Sexual Health On Call 
(SHOC), 22 Lonsdale Road, Queen’s Park, London 
NW6 6RD
Tel: +44 (0)207 604 4826
Fax: +44 (0)207 604 4826
E-mail: shoc@gp-e84025.nhs.uk 
www.smmgp.org.uk/html/news/events.php 
Information: Primary-care-based substance 
misuse treatment services are becoming well 
established, and improving. The conference is an 
ideal opportunity for those involved in developing 
services to come together to focus on where we 
are now and where we want to go in the future 
of primary care based services. It is also a forum 
for discussion about the development of services 
which focus on the person and not simply the drug, 
and an opportunity to develop and strengthen 
regional networks. This year’s conference focuses 
on ‘Bringing it Together’, how we can all work to 
improve the care of our patients who use drugs 
and/or alcohol and who may be infected or 
affected by hepatitis or HIV. As always, we value the 
input of patients, carers, users and multidisciplinary 
colleagues from the fi eld, GPs, shared care 
coordinators, service managers, DAAT offi cers, 
commissioners and shared care workers.
October
4–5 October 2007
Getting a Grip: Winning or Losing. Fourth National 
Conference on Substance and Alcohol Misuse for 
Local Authorities, the Public Service and Drug/
Alcohol Misuse Service Providers. 
Venue: Malton Hotel Killarney
Organised by / Contact: Kerry Life Education Ltd.
Tel: +44 (0)65 35135
Email: lifeed@eircom.net
http://www.kerrylifeeducation.com 
11–12 October 2007
Conference on Quasi-Coerced Treatment and other 
alternatives to imprisonment
Venue: Palace of the Parliament, Bucharest, 
Romania
Organised by / Contact: Council of Europe 
Pompidou Group and the Romanian National Anti-
Drug Agency
Information: This event is a continuation of 
efforts undertaken by the Pompidou Group 
Expert Forum on Criminal Justice to improve 
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criminal justice responses to the drug situation, by 
seeking to promote changes in the policies and 
practices concerning the management of drug-
using offenders in prison, as well as alternative 
approaches to imprisonment. Speakers’ topics will 
include: an overview of existing mechanisms in 
EU member states; a review of evidence for the 
effectiveness of Quasi-Coerced Treatment (QCT); 
and evaluation methods and cost effectiveness of 
QCT programmes.
15–16 October 2007
2007 National Conference on injecting drug use
Venue: Glasgow Radisson Hotel
Organised by / Contact: Exchange Supplies
Tel: +44 (0)1305 262244
Fax: +44 (0)1305 262255
Email: info@exchangesupplies.org 
www.exchangesupplies.org 
Information: A packed and varied programme of 
plenary sessions covering key issues and over 30 
parallel sessions, meetings, poster presentations and 
fi lms all designed to inform practice, disseminate 
research, explore policy and develop skills. Plenary 
keynote topics will include:
composition of illicit drugs: manufacture,  ■
adulterants, purity
developing our understanding of sharing, and  ■
how to reduce it
providing needle exchange to young people ■
insulin use by body-builders ■
pharmacy needle exchange ■
crack cocaine preparation and injection ■
November
8–9 November 2007
Democracy, Cities & Drugs, 3rd Conference
Venue: Venice, Italy
Organised by / Contact: Democracy, Cities and 
Drugs. Contact Thierry Charlois
Tel: +33 (0)1 40 64 49 00 
Email: conference-venice@democitydrug.org 
www.democitydrug.org 
Information: 3rd conference on local, integrated 
& participative responses to the issue of drugs use. 
Includes sessions covering the following topics: 
The political environment of local partnerships ■
Epidemiology and new trends of drug using ■
Judges and local partnerships  ■
Innovative practices ■
Sharing practices with Central, Eastern  ■
European and Balkan countries
Drugs and Cities: What images? ■
Integration between care facilities and law  ■
enforcement
March 2008
13–14 March 2008
NDTC 08: National Drug Treatment Conference
Venue: Radisson Hotel, Glasgow
Organised by / Contact: Exchange Supplies
Tel: +44(0)1305 262244
Fax: +44 (0)1305 262255 
Email: info@exchangesupplies.org
www.exchangesupplies.org 
Information: 2008 sees the introduction of a 
new UK drugs strategy and review of the clinical 
guidelines infl uencing the way practitioners work 
with drug users. The NDTC is the biggest forum for 
the drug treatment fi eld to discuss key issues and 
help shape the year ahead.
Key plenary and workshop presentation titles  ■
will include:
The new drug strategy: implications for policy  ■
and practice
‘Natural recovery’ from problematic drug use ■
Families: how can we help? How can they help? ■
More drug treatment with less money ■
Understanding the heroin and cocaine supply  ■
chain
Post-release initiatives for drug-using prisoners ■
Alcohol, cannabis, cocaine, ecstasy (ACCE): the  ■
post heroin and crack generation
Brief interventions with alcohol: why not with  ■
drugs?
Are the NICE guidelines nice enough? ■
Engaging black and minority ethnic  ■
communities in drug service development
May 2008
11–15 May 2008
International Harm Reduction Association, 19th 
International Conference: Towards a global 
approach 
Venue: Palacio de Congresos, Fira de Barcelona, 
Spain
Organised by / Contact: International Harm 
Reduction Association (IHRA)
Tel: +44 (0) 207 462 6997
Fax: +44 (0) 207 462 6999
Email: info@ihraconferences.com 
www.ihra.net/Barcelona/Home 
Information: IHRA’s harm reduction conferences 
have been held around the world each year since 
1990, and the next event in this highly successful 
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series takes place in the city of Barcelona. Over 
fi ve days, this conference will be the main 
meeting point for those interested in harm 
reduction, and an invaluable platform for 
debate, discussion, and the dissemination of 
new and evolving good practice in addressing 
drug use and associated harm. 
29–31 May 2008
EUROPAD 8 Conference
Venue: Kempinski Hotel, Sofi a, Bulgaria
Organised by / Contact: EUROPAD: European 
Opiate Addiction Treatment Association 
www.europad.org 
Information: Further details to be announced. 
The Alcohol and Drug Research Unit 
(ADRU) of the Health Research Board is 
a multi-disciplinary team of researchers 
and information specialists who provide 
objective, reliable and comparable 
information on the drug situation, its 
consequences and responses in Ireland.
The ADRU maintains two national drug-
related surveillance systems and is the 
national focal point for the European 
Monitoring Centre for Drugs and Drug 
Addiction. The unit also manages the 
National Documentation Centre on Drug 
Use.
The ADRU disseminates research fi ndings, 
information and news through its 
quarterly newsletter, Drugnet Ireland, and 
other publications. Through its activities, 
the ADRU aims to inform policy and 
practice in relation to drug use.
Sarah Fanagan
At the end of July 2007, Sarah Fanagan left 
the Alcohol and Drug Research Unit (ADRU) 
where she had worked as an analyst with 
the National Drug Treatment Reporting 
System since August 2005. During this time 
Sarah made a signifi cant contribution to the 
NDTRS. She worked on the collection of 
data for 2004 to 2006 from the HSE areas 
outside Dublin, Kildare and Wicklow, the 
development of a computerised data-entry 
programme, and the design of a pilot exit 
form. Sarah’s intelligence and warmth and 
her calm and analytical approach to her work 
will be missed by her colleagues in the ADRU 
and by those outside the HRB with whom 
she worked in data co-ordination. Sarah got 
married in August and has now moved to 
Abu Dhabi. We wish her and her husband 
Fiachra every happiness and success in their 
new life together.
Drugnet Ireland mailing list
If you wish to have your name included on 
the mailing list for future issues of Drugnet 
Ireland, please send your contact details to:
Alcohol and Drug Research Unit
Health Research Board
Knockmaun House
42–47 Lower Mount Street
Dublin 2
Tel: 01 2345 127
Email: adru@hrb.ie
Please indicate whether you would also 
like to be included on the mailing list for 
Drugnet Europe or Drugs in focus.
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